SG111083A1 - Prevention and treatment of amyloidogenic disease - Google Patents
Prevention and treatment of amyloidogenic diseaseInfo
- Publication number
- SG111083A1 SG111083A1 SG200205898A SG200205898A SG111083A1 SG 111083 A1 SG111083 A1 SG 111083A1 SG 200205898 A SG200205898 A SG 200205898A SG 200205898 A SG200205898 A SG 200205898A SG 111083 A1 SG111083 A1 SG 111083A1
- Authority
- SG
- Singapore
- Prior art keywords
- prevention
- treatment
- amyloidogenic disease
- amyloidogenic
- disease
- Prior art date
Links
- 102000009091 Amyloidogenic Proteins Human genes 0.000 title 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 title 1
- 230000003942 amyloidogenic effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/739—Lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/605—MHC molecules or ligands thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6774097P | 1997-12-02 | 1997-12-02 | |
US8097098P | 1998-04-07 | 1998-04-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG111083A1 true SG111083A1 (en) | 2005-05-30 |
Family
ID=26748211
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG200205898A SG111083A1 (en) | 1997-12-02 | 1998-11-30 | Prevention and treatment of amyloidogenic disease |
Country Status (38)
Country | Link |
---|---|
US (26) | US20040171815A1 (de) |
EP (5) | EP1994937B1 (de) |
JP (4) | JP4677094B2 (de) |
KR (3) | KR100936419B1 (de) |
CN (1) | CN100374151C (de) |
AR (1) | AR020050A1 (de) |
AT (4) | ATE493149T1 (de) |
AU (1) | AU1706199A (de) |
BG (1) | BG104562A (de) |
BR (1) | BR9815357A (de) |
CA (1) | CA2312920C (de) |
CO (1) | CO4980846A1 (de) |
CY (3) | CY1108331T1 (de) |
CZ (1) | CZ303137B6 (de) |
DE (7) | DE06075479T1 (de) |
DK (4) | DK1679080T3 (de) |
EA (3) | EA009283B1 (de) |
EE (1) | EE05377B1 (de) |
ES (4) | ES2262460T1 (de) |
GE (2) | GEP20053715B (de) |
HK (2) | HK1095265A1 (de) |
HR (2) | HRP20000443B1 (de) |
HU (2) | HU228061B1 (de) |
ID (1) | ID25504A (de) |
IL (5) | IL136252A0 (de) |
IS (1) | IS5500A (de) |
MY (1) | MY134906A (de) |
NO (3) | NO328865B1 (de) |
NZ (1) | NZ504569A (de) |
PE (1) | PE20001383A1 (de) |
PL (2) | PL202706B1 (de) |
PT (4) | PT1994937E (de) |
SA (1) | SA99191269B1 (de) |
SG (1) | SG111083A1 (de) |
SI (4) | SI1679080T1 (de) |
TR (1) | TR200001608T2 (de) |
TW (1) | TWI239847B (de) |
WO (1) | WO1999027944A1 (de) |
Families Citing this family (294)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0866805A1 (de) | 1995-12-12 | 1998-09-30 | Karolinska Innovations AB | Peptide, das die KLVFF Sequenz von beta-Amyloid bindet |
US8173127B2 (en) * | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
US6703015B1 (en) | 1999-09-03 | 2004-03-09 | Ramot At Tel-Aviv University Ltd. | Filamentous bacteriophage displaying an β-amyloid epitope |
US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
US6761888B1 (en) * | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US7588766B1 (en) * | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US7179892B2 (en) * | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US20050059802A1 (en) * | 1998-04-07 | 2005-03-17 | Neuralab Ltd | Prevention and treatment of amyloidogenic disease |
US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
NZ507727A (en) * | 1998-05-21 | 2003-11-28 | Univ Tennessee Res Foundation | Methods for amyloid removal using anti-amloid antibodies |
US7060670B1 (en) | 1999-05-05 | 2006-06-13 | Neurochem (International) Limited | Stereoselective antifibrillogenic peptides and peptidomimetics thereof |
AU781469B2 (en) | 1999-05-13 | 2005-05-26 | Wyeth Holdings Corporation | Adjuvant combination formulations |
AU2008203784B2 (en) * | 1999-05-28 | 2012-01-19 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidogenic disease |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
UA81216C2 (en) * | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
AU2005202644B2 (en) * | 1999-06-01 | 2009-03-05 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidogenic disease |
AR024558A1 (es) * | 1999-06-01 | 2002-10-16 | Neuralab Ltd | Composiciones del peptido a-beta y procesos para producir las mismas |
AU780474B2 (en) | 1999-06-16 | 2005-03-24 | Boston Biomedical Research Institute Incorporated | Immunological control of beta-amyloid levels in vivo |
WO2001018169A2 (en) * | 1999-09-03 | 2001-03-15 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Agents and compositions and methods for diagnostic and/or treating or preventing plaque forming diseases |
US7384640B1 (en) | 1999-09-30 | 2008-06-10 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant |
US20020094335A1 (en) * | 1999-11-29 | 2002-07-18 | Robert Chalifour | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases |
US20070135337A2 (en) * | 1999-11-29 | 2007-06-14 | Neurochem (International) Limited | Vaccine for the Prevention and Treatment of Alzheimer's and Amyloid Related Diseases |
CN1414976A (zh) * | 1999-12-08 | 2003-04-30 | 明德塞特生物制药(美国)公司 | 作为免疫原的嵌合肽及其抗体,以及利用嵌合肽或抗体进行免疫的方法 |
EP1752472A3 (de) * | 1999-12-08 | 2007-04-25 | Intellect Neurosciences, Inc. | Schimärische Amyloid-beta-Peptide |
AU783144B2 (en) * | 2000-02-21 | 2005-09-29 | H. Lundbeck A/S | Novel method for down-regulation of amyloid |
WO2001062284A2 (en) * | 2000-02-21 | 2001-08-30 | Pharmexa A/S | Novel method for down-regulation of amyloid |
CZ306683B6 (cs) | 2000-02-24 | 2017-05-03 | Washington University | Léčivo pro prevenci nebo léčení preklinické nebo klinické Alzheimerovy nemoci |
CA2404237C (en) | 2000-04-05 | 2010-01-26 | University Of Tennessee Research Corporation | Methods of investigating, diagnosing, and treating amyloidosis |
ATE286072T1 (de) * | 2000-05-22 | 2005-01-15 | Univ New York | Synthetische immunogene jedoch nicht amyloidogene peptide, die homolog zu amyloid beta sind und deren verwendung zur induktion einer immunantwort gegen amyloid beta und amyloidaggregate |
JP2003516929A (ja) * | 2000-06-01 | 2003-05-20 | ニユーララブ・リミテツド | アミロイド形成性疾患の予防および治療 |
DE60118913T2 (de) * | 2000-06-20 | 2007-01-25 | The Governing Council Of The University Of Toronto, Toronto | Transgenes tiermodell für neurodegenerative erkrankungen |
US7371920B2 (en) | 2000-06-20 | 2008-05-13 | The Governing Council Of The University Of Toronto | Transgenic mouse model of neurodegenerative disorders |
WO2002000885A2 (en) | 2000-06-23 | 2002-01-03 | American Cyanamid Company | Assembly of wild-type and chimeric influenza virus-like particles (vlps) |
AU6882801A (en) * | 2000-06-28 | 2002-01-08 | Prana Biotechnology Ltd | Neurotoxic oligomers |
CA2414772C (en) | 2000-07-07 | 2011-06-28 | Jan Naslund | Prevention and treatment of alzheimer's disease |
AU2007200047B2 (en) * | 2000-07-07 | 2009-11-26 | Bioarctic Neuroscience Ab | Prevention and treatment of Alzheimer's disease |
WO2002021141A2 (en) * | 2000-09-06 | 2002-03-14 | Aventis Pharma S.A. | Methods and compositions for diseases associated with amyloidosis |
WO2002025279A2 (en) * | 2000-09-19 | 2002-03-28 | Evotec Neurosciences Gmbh | Use of amyloid precursor protein for treating brain amyloidosis |
IL139308A0 (en) * | 2000-10-26 | 2001-11-25 | Marikovsky Moshe | Peptides from amyloid precursor protein which inhibit tumor growth and metastasis |
EE200300172A (et) | 2000-11-10 | 2003-06-16 | Wyeth Holdings Corporation | Antigeenne kompositsioon ja adjuvantsegu |
ATE466078T1 (de) | 2000-11-29 | 2010-05-15 | Univ Rochester | Helfervirus-freie herpesvirus-amplifikatpartikel und deren verwendungen |
TWI255272B (en) * | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
CN100422210C (zh) | 2000-12-28 | 2008-10-01 | Wyeth公司 | 来自肺炎链球菌的重组防护蛋白质 |
US7264810B2 (en) | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
US6815175B2 (en) | 2001-03-16 | 2004-11-09 | Cornell Research Foundation, Inc. | Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder |
GB0109297D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
EP1385545B1 (de) | 2001-04-30 | 2009-01-07 | Eli Lilly And Company | HUMANISIERTE ANTIKÖRPER DIE DAS BETA-AMYLOID PEPTID ERKENNEN& x9; |
ATE409047T1 (de) | 2001-04-30 | 2008-10-15 | Lilly Co Eli | Humanisierte antikörper |
US8092791B2 (en) | 2001-05-23 | 2012-01-10 | University Of Rochester | Method of producing herpes simplex virus amplicons, resulting amplicons, and their use |
US6906169B2 (en) | 2001-05-25 | 2005-06-14 | United Biomedical, Inc. | Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide |
ATE451386T1 (de) | 2001-06-07 | 2009-12-15 | Wyeth Corp | Mutantenformen von cholera holotoxin als adjuvans |
JP2005508143A (ja) | 2001-06-07 | 2005-03-31 | ワイス・ホールデイングス・コーポレーシヨン | アジュバントとしてのコレラホロトキシンの突然変異形 |
WO2003006893A2 (en) | 2001-07-09 | 2003-01-23 | Elan Pharmaceuticals, Inc. | Methods of inhibiting amyloid toxicity |
US7829087B2 (en) | 2001-07-09 | 2010-11-09 | Elan Pharmaceuticals, Inc. | Methods of treating cognitive impairment |
WO2003015617A2 (en) * | 2001-08-17 | 2003-02-27 | Washington University | Assay method for alzheimer's disease |
EP1944040B1 (de) | 2001-08-17 | 2012-08-01 | Washington University | Assay-Verfahren für Alzheimer |
JP2005500389A (ja) * | 2001-08-17 | 2005-01-06 | イーライ・リリー・アンド・カンパニー | Aβに関連する病態および疾患を治療するための、可溶性Aβに高い親和性を有する抗体の使用 |
CA2451998A1 (en) * | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | Anti-a.beta. antibodies |
US20060073149A1 (en) * | 2001-08-17 | 2006-04-06 | Bales Kelly R | Rapid improvement of cognition in condition related to abeta |
MY144532A (en) | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
US20030082191A1 (en) * | 2001-08-29 | 2003-05-01 | Poduslo Joseph F. | Treatment for central nervous system disorders |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
AU2002357007A1 (en) | 2001-11-21 | 2003-06-10 | New York University | SYNTHETIC IMMUNOGENIC BUT NON-DEPOSIT-FORMING POLYPEPTIDES AND PEPTIDES HOMOLOGOUS TO AMYLOID Beta, PRION PROTEIN, AMYLIN, Alpha-SYNUCLEIN, OR POLYGLUTAMINE REPEATS FOR INDUCTION OF AN IMMUNE RESPONSE THERETO |
US20040052928A1 (en) | 2002-09-06 | 2004-03-18 | Ehud Gazit | Peptides and methods using same for diagnosing and treating amyloid-associated diseases |
AR038568A1 (es) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
US20040001848A1 (en) * | 2002-03-01 | 2004-01-01 | Szu-Yi Chou | Method of producing disease-specific antigens |
CA2477675C (en) | 2002-03-05 | 2013-05-21 | Ramot At Tel-Aviv University Ltd. | Immunizing composition and method for inducing an immune response against the .beta.-secretase cleavage site of amyloid precursor protein |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
EP1575529A4 (de) * | 2002-07-17 | 2007-08-08 | Intellect Neurosciences Inc | Peptide und verfahren zur untersuchung von immunogenen peptid-vakzinen gegen alzheimer-krankheit |
CN101711865A (zh) | 2002-07-19 | 2010-05-26 | 希托斯生物技术股份公司 | 含有淀粉样β1-6抗原阵列的疫苗组合物 |
US7252953B2 (en) | 2002-08-13 | 2007-08-07 | United States Of America Department Of Veterans Affairs | Method of detecting and preventing Alzheimer's disease, particularly at prodromal and early stages |
US7785608B2 (en) | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
US9535076B2 (en) | 2002-09-12 | 2017-01-03 | The Regents Of The University Of California | Methods and compositions for eliciting an amyloid-selective immune response |
US8871447B2 (en) | 2002-09-12 | 2014-10-28 | The Regents Of The University Of California | Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence |
KR20050071564A (ko) * | 2002-10-09 | 2005-07-07 | 리나트 뉴로사이언스 코퍼레이션 | 아밀로이드 베타 펩티드에 대한 항체를 사용하여알츠하이머병을 치료하는 방법 및 그의 조성물 |
US8697082B2 (en) | 2002-11-01 | 2014-04-15 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US9034337B2 (en) | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
TW200509968A (en) * | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
US8506959B2 (en) * | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
CN100450551C (zh) * | 2002-11-29 | 2009-01-14 | 中国医学科学院基础医学研究所 | 用于治疗和预防阿尔茨海默病的重组腺相关病毒基因疫苗及其用途 |
US20070010435A1 (en) | 2002-12-19 | 2007-01-11 | New York University | Method for treating amyloid disease |
DE10303974A1 (de) * | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
ZA200505782B (en) * | 2003-02-01 | 2006-09-27 | Neuralab Ltd | Active immunization to generate antibodies to soluble A-beta |
AU2004208962B2 (en) * | 2003-02-10 | 2010-07-15 | To-Bbb Holding B.V. | Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions |
WO2004071408A2 (en) | 2003-02-10 | 2004-08-26 | Applied Molecular Evolution, Inc. | Aβ BINDING MOLECULES |
US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
CA2519511A1 (en) * | 2003-03-17 | 2004-09-30 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
KR100546066B1 (ko) * | 2003-03-21 | 2006-01-26 | 한국생명공학연구원 | 베타아밀로이드 유전자의 다중 연결체를 발현하는 형질전환 식물 세포 및 이로부터 배양된 식물 |
WO2004087733A2 (en) * | 2003-03-28 | 2004-10-14 | New York University | Prevention and treatment of alzheimer amyloid deposition |
US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
ES2246105B1 (es) | 2003-05-08 | 2007-03-01 | Araclon Biotech, S.L. | Uso de anticuerpos para el tratamiento de enfermedades amiloideas. |
US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
PE20050627A1 (es) | 2003-05-30 | 2005-08-10 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
JP4888876B2 (ja) * | 2003-06-13 | 2012-02-29 | 田平 武 | アルツハイマー病の治療のための組換えアデノ随伴ウィルスベクター |
AU2004251522C1 (en) | 2003-06-30 | 2011-12-15 | Tel Aviv University Future Technology Development L.P. | Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases |
WO2005014041A2 (en) * | 2003-07-24 | 2005-02-17 | Novartis Ag | Use of an amyloid beta dna vaccine for the treatment and/or prevention of amyloid diseases |
US7807171B2 (en) | 2003-07-25 | 2010-10-05 | Ac Immune Sa | Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers |
GB0321615D0 (en) | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
CA2545152A1 (en) * | 2003-11-07 | 2005-05-26 | Howard J. Federoff | Compositions and methods of treating neurological diseases |
WO2005047860A2 (en) | 2003-11-08 | 2005-05-26 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
AR047062A1 (es) * | 2003-12-17 | 2006-01-04 | Wyeth Corp | Conjugados portadores de peptidos inmunogenicos a beta y metodos para producirlos |
US20050225165A1 (en) * | 2004-04-13 | 2005-10-13 | Naik Sanjeev M | Brake by-wire control system |
CA2564562A1 (en) | 2004-04-26 | 2005-11-03 | Innate Pharma | Adjuvant composition and methods for its use |
GB0410220D0 (en) | 2004-05-07 | 2004-06-09 | Kirkham Lea Ann | Mutant pneumolysin proteins |
SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
EP1761276B1 (de) * | 2004-06-25 | 2013-07-24 | ID Biomedical Corporation of Quebec | Zusammensetzungen und methoden zur behandlung neurologischer erkrankungen |
WO2006014638A2 (en) * | 2004-07-19 | 2006-02-09 | The General Hospital Corporation | ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS |
MX2007000998A (es) | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
CA2576405A1 (en) | 2004-08-11 | 2006-02-16 | Mitsubishi Chemical Corporation | Antibody and utilization of the same |
US7807804B2 (en) * | 2004-10-05 | 2010-10-05 | Wyeth Llc | Methods and compositions for improving recombinant protein production |
US20090035797A1 (en) * | 2004-10-15 | 2009-02-05 | Hancock William S | Detection of Disease Associated Proteolysis |
GB0424563D0 (en) | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
AR052051A1 (es) | 2004-12-15 | 2007-02-28 | Neuralab Ltd | Anticuerpos ab humanizados usados en mejorar la cognicion |
JP2008524247A (ja) * | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミテッド | 認知の改善における使用のためのアミロイドβ抗体 |
US20110020237A1 (en) * | 2005-01-14 | 2011-01-27 | Glabe Charles G | Compositions and Methods for Inhibiting Drusen Formation and for Diagnosing or Treating Drusen-Related Disorders |
EP1841455A1 (de) | 2005-01-24 | 2007-10-10 | Amgen Inc. | Humanisierter anti-amyloid-antikörper |
BRPI0606867A2 (pt) * | 2005-01-28 | 2009-07-21 | Wyeth Corp | formulação lìquida; forma de dosagem unitária farmacêutica; kit; recipiente; método para aumentar a estabilidade de um polipeptìdeo de ligação a antìgeno numa formulação; método para preparar uma forma de dosagem unitária farmacêutica; formulação estável; formulação; e produto terapêutico |
GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
WO2006112553A2 (en) * | 2005-04-20 | 2006-10-26 | Dnavec Corporation | Highly safe intranasally administrable gene vaccines for treating alzheimer's disease |
CN101228272A (zh) * | 2005-04-20 | 2008-07-23 | 生物载体株式会社 | 用于治疗阿尔茨海默病的具有较高安全性的经鼻腔内给药基因疫苗 |
MY148086A (en) * | 2005-04-29 | 2013-02-28 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same |
WO2006119352A2 (en) * | 2005-05-03 | 2006-11-09 | University Of South Florida | Method of treating cognitive decline and synaptic loss related to alzheimer's disease |
RU2406529C2 (ru) | 2005-05-05 | 2010-12-20 | Мерк Шарп Энд Домэ Корп. | Композиции пептидного конъюгата и способы для профилактики и лечения болезни альцгеймера |
WO2006126682A1 (ja) * | 2005-05-27 | 2006-11-30 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | アルツハイマー病の予防・治療用ワクチン |
EA201100177A1 (ru) | 2005-06-17 | 2011-06-30 | Элан Фарма Интернэшнл Лимитед | СПОСОБЫ ОЧИСТКИ АНТИТЕЛ К β-АМИЛОИДУ |
JP4921468B2 (ja) | 2005-07-10 | 2012-04-25 | アダプティブ スペクトラム アンド シグナル アラインメント インコーポレイテッド | マージンおよび帯域の適応制御 |
WO2007056401A1 (en) * | 2005-11-09 | 2007-05-18 | Merck & Co., Inc. | Method for identifying modulators of osbp useful for treating alzheimer's disease |
CA2632218A1 (en) * | 2005-11-28 | 2007-10-11 | Zymogenetics, Inc. | Il-21 receptor antagonists |
US20070122413A1 (en) * | 2005-11-28 | 2007-05-31 | Sivakumar Pallavur V | Il-21 antagonists |
BRPI0619249A2 (pt) | 2005-11-30 | 2011-09-20 | Abbott Lab | anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos |
IL297746A (en) | 2005-11-30 | 2022-12-01 | Abbvie Inc | Monoclonal antibodies against amyloid beta protein and uses thereof |
WO2007067512A2 (en) * | 2005-12-08 | 2007-06-14 | Merck & Co., Inc. | Method for identifying modulators of adprh useful for treating alzheimer's disease |
PT2361638E (pt) * | 2005-12-12 | 2014-04-17 | Ac Immune Sa | Anticorpos monoclonais específicos beta 1-42 com propriedades terapêuticas |
UY30003A1 (es) | 2005-12-12 | 2007-08-31 | Hoffmann La Roche | Anticuerpos glicosilados en la region variable |
KR20080103560A (ko) * | 2006-02-22 | 2008-11-27 | 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 | 항 아밀로이드-β-펩티드 항체 생산 유도용 펩티드 백신 |
DE602007011415D1 (de) | 2006-03-23 | 2011-02-03 | Bioartic Neuroscience Ab | Verbesserte protofibrilselektive antikörper und deren verwendung |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
WO2009017467A1 (en) | 2007-07-27 | 2009-02-05 | Elan Pharma International Limited | Treatment of amyloidogenic diseases |
US7479550B2 (en) | 2006-06-02 | 2009-01-20 | The Board Of Regents Of The University Of Texas System | Amyloid β gene vaccines |
WO2008011348A2 (en) * | 2006-07-14 | 2008-01-24 | Ac Immune S.A. | Humanized antibody against amyloid beta |
US20090123488A1 (en) * | 2006-08-14 | 2009-05-14 | Thymon, Llc | Compositions and methods for the treatment and prophylaxis of Alzheimer's disease |
KR20090069330A (ko) * | 2006-10-12 | 2009-06-30 | 와이어쓰 | 유백광/응집체를 감소시키기 위한 항체 용액 중의 이온 강도의 변화 |
WO2008070284A2 (en) * | 2006-10-16 | 2008-06-12 | Johnnie B. Byrd, Sr. Alzheimer's Center And Research Institute | Amyloid beta peptides and methods of uses thereof |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
US20080214987A1 (en) | 2006-12-22 | 2008-09-04 | Nanomed Devices, Inc. | Microdevice And Method For Transdermal Delivery And Sampling Of Active Substances |
IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses. |
PL2099826T3 (pl) | 2007-01-05 | 2014-04-30 | Univ Zuerich | Przeciwciało przeciwko beta-amyloidowi i jego zastosowania |
PL2104682T3 (pl) | 2007-01-11 | 2017-03-31 | Michael Bacher | Diagnostyka i leczenie choroby Alzheimera i innych chorób neurodegeneracyjnych |
EA020979B1 (ru) | 2007-01-18 | 2015-03-31 | Эли Лилли Энд Компани | ПЭГИЛИРОВАННЫЕ Fab-ФРАГМЕНТЫ АНТИТЕЛ К ПЕПТИДУ Aβ |
DK3067066T3 (da) | 2007-02-23 | 2019-05-20 | Prothena Biosciences Ltd | Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom |
US8147833B2 (en) | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
WO2008106657A2 (en) * | 2007-03-01 | 2008-09-04 | Intezyne Technologies, Inc. | Encapsulated amyloid-beta peptides |
WO2008104580A1 (en) | 2007-03-01 | 2008-09-04 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
EP2146746A4 (de) * | 2007-04-18 | 2011-03-23 | Janssen Alzheimer Immunotherap | Vorbeugung und behandlung von zerebraler amyloid-angiopathy |
US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
EP2012122A1 (de) * | 2007-07-06 | 2009-01-07 | Medigene AG | Strukturproteine von mutierten Parvoviren als Impfstoffe |
JP2010528583A (ja) * | 2007-06-11 | 2010-08-26 | エーシー イミューン ソシエテ アノニム | アミロイドβに対するヒト化抗体 |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
EP2170389B1 (de) * | 2007-06-12 | 2014-10-29 | AC Immune S.A. | Humanisierte antikörper gegen amyloid beta |
US8613923B2 (en) * | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
EP2724728B1 (de) | 2007-06-27 | 2018-10-17 | The United States of America, as Represented by The Secretary, Department of Health and Human Services | Komplexe von il-15 und il-15r alpha und verwendungen davon |
CA2700808C (en) | 2007-09-27 | 2017-11-14 | Immunovaccine Technologies Inc. | Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo |
AU2008311366B2 (en) * | 2007-10-05 | 2015-03-12 | Ac Immune S.A. | Use of anti-amyloid beta antibody in ocular diseases |
ES2612788T3 (es) * | 2007-10-05 | 2017-05-18 | Genentech, Inc. | Métodos y composiciones para el diagnóstico y tratamiento de la amiloidosis |
PT2238166E (pt) | 2007-10-05 | 2014-02-11 | Genentech Inc | Utilização do anticorpo anti-amilóide beta em doenças oculares |
JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
US8445649B2 (en) * | 2007-10-29 | 2013-05-21 | Tao Health Life Pharma Co., Ltd. | Antibody and use thereof |
CN103772502B (zh) | 2007-12-07 | 2017-03-29 | 津莫吉尼蒂克斯公司 | 抗人il‑21单克隆抗体 |
EP2235058A2 (de) | 2007-12-21 | 2010-10-06 | Amgen, Inc | Anti-amyloid-antikörper und ihre verwendung |
WO2009090650A2 (en) * | 2008-01-16 | 2009-07-23 | Ben-Gurion University Of The Negev Research And Development Authority | Vaccine for alzheimer's disease |
WO2009146523A1 (en) * | 2008-06-05 | 2009-12-10 | Immunovaccine Technologies Inc. | Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance |
EP2334332A4 (de) * | 2008-09-05 | 2013-01-09 | Id Biomedical Corp Quebec | Neue zusammensetzungen und hilfsstoffe |
US20110263450A1 (en) * | 2008-09-26 | 2011-10-27 | The University Of Melbourne | Alzheimer's disease biomarkers |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
JPWO2010050585A1 (ja) * | 2008-10-31 | 2012-03-29 | ディナベック株式会社 | アルツハイマー病治療用ベクター |
KR20110081282A (ko) | 2008-11-05 | 2011-07-13 | 와이어쓰 엘엘씨 | 베타―용혈성 연쇄구균 (bhs) 질환의 예방을 위한 다성분 면역원성 조성물 |
BRPI0923157B1 (pt) | 2008-12-19 | 2021-12-28 | University Of Zürich | Anticorpos anti-alfa-sinucleína e seus fragmentos, seus usos e método de preparação, composição compreendendo-os, bem como kit e métodos para o diagnóstico e monitoramento de uma doença sinucleinopática |
US8614297B2 (en) | 2008-12-22 | 2013-12-24 | Hoffmann-La Roche Inc. | Anti-idiotype antibody against an antibody against the amyloid β peptide |
US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
CA2753886C (en) | 2009-03-02 | 2018-06-12 | Catholic Healthcare West | Diagnostic devices and methods of use |
FR2945538B1 (fr) | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
AU2010282340B2 (en) | 2009-08-13 | 2016-12-22 | The Johns Hopkins University | Methods of modulating immune function |
ES2548913T3 (es) | 2009-09-11 | 2015-10-21 | Probiodrug Ag | Derivados heterocíclicos como inhibidores de glutaminil ciclasa |
US9757398B2 (en) | 2010-02-20 | 2017-09-12 | Euroespes Biotecnnologia, S.L. | Prevention and treatment of alzheimer's disease by amyloid beta peptide and sphin-gosine-1-phosphate |
EP2542571B1 (de) * | 2010-03-03 | 2016-05-25 | The University of British Columbia | Oligomer-spezifisches amyloid-beta-epitop und antikörper dazu |
EP2542549B1 (de) | 2010-03-03 | 2016-05-11 | Probiodrug AG | Glutaminylcyclase-hemmer |
PE20130527A1 (es) | 2010-03-03 | 2013-05-09 | Boehringer Ingelheim Int | Polipeptidos de union a a-beta biparatopicos |
EP2545047B9 (de) | 2010-03-10 | 2015-06-10 | Probiodrug AG | Heterocyclische hemmer der glutaminylcyclase (qc, ec 2.3.2.5) |
CA2796339C (en) | 2010-04-15 | 2020-03-31 | Abbott Laboratories | Amyloid-beta binding proteins |
JP5945532B2 (ja) | 2010-04-21 | 2016-07-05 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
EP2576617B1 (de) | 2010-06-04 | 2016-04-27 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin | MONOKLONALE ANTIKÖRPER, DIE AUF Aß-OLIGOMERE ZIELEN |
RU2607368C2 (ru) | 2010-07-30 | 2017-01-10 | Ац Иммуне С.А. | Безопасные и функциональные гуманизированные антитела |
EP3527220A1 (de) | 2010-08-12 | 2019-08-21 | AC Immune S.A. | Manipulation von impfstoffen |
EP2603524A1 (de) | 2010-08-14 | 2013-06-19 | AbbVie Inc. | Amyloid-beta-bindende proteine |
CA2808975C (en) | 2010-08-23 | 2018-10-30 | Wyeth Llc | Stable formulations of neisseria meningitidis rlp2086 antigens |
JP5976652B2 (ja) | 2010-09-10 | 2016-08-24 | ワイス・エルエルシー | 髄膜炎菌orf2086抗原の非脂質化変異体 |
WO2012051498A2 (en) | 2010-10-15 | 2012-04-19 | The Board Of Regents Of The University Of Texas System | Antibodies that bind amyloid oligomers |
CA2813833C (en) | 2010-10-26 | 2020-09-22 | Ac Immune S.A. | Liposome-based construct comprising a peptide modified through hydrophobic moieties |
MX2013005413A (es) | 2010-11-15 | 2014-02-27 | Univ Ramot | Analogos de dipeptidos para el tratamiento de afecciones asociadas con la formacion de fibrillas amiloides. |
WO2012123563A1 (en) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
RU2473133C2 (ru) * | 2011-03-30 | 2013-01-20 | Государственное образовательное учреждение высшего профессионального образования "Северо-Осетинская государственная медицинская академия" Министерства здравоохранения и социального развития РФ | Способ профилактики системного амилоидоза и его нефропатической формы у экспериментальных животных |
ES2602794T3 (es) | 2011-03-31 | 2017-02-22 | Pfizer Inc | Piridinonas bicíclicas novedosas |
CN102807621B (zh) * | 2011-06-01 | 2016-04-13 | 厦门大学 | 包含白喉毒素无毒突变体crm197或其片段的融合蛋白 |
WO2012172449A1 (en) | 2011-06-13 | 2012-12-20 | Pfizer Inc. | Lactams as beta secretase inhibitors |
LT2723379T (lt) | 2011-06-23 | 2018-10-25 | Biogen International Neuroscience Gmbh | Anti-alfa sinukleiną rišančios molekulės |
US9926353B2 (en) | 2011-07-19 | 2018-03-27 | New York University | Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides |
WO2013013056A1 (en) | 2011-07-19 | 2013-01-24 | New York University | Method for treating amyloid disease |
CN102895659B (zh) * | 2011-07-29 | 2014-10-29 | 复旦大学 | 一种防治老年痴呆症复合疫苗及其制备方法 |
US20150065449A1 (en) | 2011-08-12 | 2015-03-05 | Florida State University Research Foundation, Inc. | Treating Amyloidoses With A Vitamin B12 Composition Including Melatonin, Resveratrol, and EGCG |
WO2013025607A1 (en) * | 2011-08-12 | 2013-02-21 | The Florida State University Research Foundation Inc. | Methods of treating amyloidoses with vitamin b12 and test for detecting amyloid-beta peptides |
WO2013030713A1 (en) | 2011-08-31 | 2013-03-07 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds |
PT2579042E (pt) | 2011-10-04 | 2014-09-09 | Affiris Ag | Método para detecção de anticorpos específicos para a numa amostra biológica. |
EP2771030A4 (de) * | 2011-10-24 | 2015-07-22 | Intellect Neurosciences Inc | Zusammensetzungen und verfahren zur behandlung von proteinopathien |
JP2012102131A (ja) * | 2012-01-05 | 2012-05-31 | Elan Pharma Internatl Ltd | アミロイド形成性疾患の予防および治療 |
CN104334187B (zh) | 2012-03-09 | 2017-04-05 | 辉瑞公司 | 脑膜炎双球菌组合物及其方法 |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
EP2852597B1 (de) | 2012-05-04 | 2016-06-08 | Pfizer Inc | Heterocyclisch substituierte hexahydropyrano [3,4-d] [1,3] thiazin-amin-2-verbindungen als inhibitoren von app, bace1 bace und 2 |
EP3255049A1 (de) | 2012-06-29 | 2017-12-13 | Pfizer Inc | Neue 4-(substituierte amino)-7h-pyrrolo[2,3-d]pyrimidine als lrrk2 hemmer |
CA2882389A1 (en) | 2012-09-20 | 2014-03-27 | Pfizer Inc. | Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
US10058530B2 (en) | 2012-10-25 | 2018-08-28 | The General Hospital Corporation | Combination therapies for the treatment of Alzheimer's disease and related disorders |
CN109846862A (zh) | 2012-10-25 | 2019-06-07 | 通用医疗公司 | 治疗阿尔茨海默病及相关疾病的组合疗法 |
US9414752B2 (en) | 2012-11-09 | 2016-08-16 | Elwha Llc | Embolism deflector |
EP2931731A1 (de) | 2012-12-11 | 2015-10-21 | Pfizer Inc. | Hexahydropyrano-[3,4-d]-[1,3]-thiazin-2-aminverbindungen als bace1-inhibitoren |
EP2935282A1 (de) | 2012-12-19 | 2015-10-28 | Pfizer Inc. | Carbocyclisch und heterocyclisch substituierte hexahydropyrano[3,4-d]-[1,3]thiazin-2-amin-verbindungen |
EP2941269B1 (de) | 2013-01-07 | 2020-12-09 | Mucosal Vaccine Technologies LLC | Therapeutische impfstoffe zur behandlung von herpes-simplex-virus-typ 2-infektionen |
EP2956458B1 (de) | 2013-02-13 | 2017-08-09 | Pfizer Inc | Heteroarylsubstituierte hexahydropyrano[3,4-d][1,3]thiazin-2-amin-verbindungen |
US9233981B1 (en) | 2013-02-15 | 2016-01-12 | Pfizer Inc. | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
JP6505023B2 (ja) | 2013-02-19 | 2019-04-24 | ファイザー・インク | Cnsおよび他の障害を治療するための、pde4アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物 |
JP6446377B2 (ja) | 2013-03-08 | 2018-12-26 | ファイザー・インク | 免疫原性融合ポリペプチド |
WO2014159614A1 (en) * | 2013-03-14 | 2014-10-02 | Flow Pharma, Inc. | Adjuvant and antigen particle formulation |
US9102752B2 (en) | 2013-03-15 | 2015-08-11 | United Biomedical, Inc. | Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type |
EP2787347A1 (de) | 2013-04-03 | 2014-10-08 | Affiris AG | Verfahren zur Erkennung von Aß-spezifischen Antikörpern in einer biologischen Probe |
US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
US10195257B2 (en) | 2013-07-28 | 2019-02-05 | Qantu Therapeutics, Inc. | Vaccine formulations comprising quillaja desacylsaponins and beta amyloid peptides or tau protein to induce a Th2 immune response |
WO2015033251A2 (en) | 2013-09-08 | 2015-03-12 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
ES2742078T3 (es) | 2013-10-04 | 2020-02-13 | Pfizer | Piridonas bicíclicas novedosas como moduladores de gamma-secretasa |
EP3060205A4 (de) | 2013-10-22 | 2017-06-28 | The General Hospital Corporation | Cromolynderivate und zugehörige verfahren für bildgebung und behandlung |
EP3083618B1 (de) | 2013-12-17 | 2018-02-21 | Pfizer Inc | Neuartige 3,4-disubstituierte-1h-pyrrolo[2,3-b]pyridine und 4,5-disubstituierte 7h-pyrrolo[2,3-c]pyridazine als lrrk2-hemmer |
EA031419B1 (ru) | 2014-04-01 | 2018-12-28 | Пфайзер Инк. | ХРОМЕН И 1,1a,2,7b-ТЕТРАГИДРОЦИКЛОПРОПА[c]ХРОМЕН ПИРИДОПИРАЗИНДИОНЫ В КАЧЕСТВЕ МОДУЛЯТОРА ГАММА-СЕКРЕТАЗЫ |
EP3129388A1 (de) | 2014-04-10 | 2017-02-15 | Pfizer Inc. | 2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl-1,3-thiazol-4-yl-amide |
WO2015165961A1 (en) | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
FI3137094T3 (fi) | 2014-04-29 | 2023-03-20 | Advantage Therapeutics Inc | Alzheimerin taudin (ad) hoitaminen ja ehkäiseminen |
EP3137093B1 (de) * | 2014-04-29 | 2017-09-13 | Affiris AG | Behandlung und prävention von alzheimer |
WO2015165964A1 (en) * | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
WO2015165971A1 (en) * | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
AU2015277379B2 (en) * | 2014-06-17 | 2017-06-29 | Academia Sinica | Humanized anti-IgE antibodies that crosslink CD23 on B lymphocytes but do not sensitize mast cells |
EP3166970B1 (de) | 2014-07-10 | 2021-03-10 | BioArctic AB | Verbesserte ass-protofibrilenbindende antikörper |
US10131669B2 (en) | 2014-07-24 | 2018-11-20 | Pfizer Inc. | Pyrazolopyrimidine compounds |
KR102061952B1 (ko) | 2014-08-06 | 2020-01-02 | 화이자 인코포레이티드 | 이미다조피리다진 화합물 |
MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
JP6628805B2 (ja) | 2015-02-03 | 2020-01-15 | ファイザー・インク | 新規シクロプロパベンゾフラニルピリドピラジンジオン |
CN107249626A (zh) | 2015-02-19 | 2017-10-13 | 辉瑞大药厂 | 脑膜炎奈瑟球菌组合物及其方法 |
WO2016203347A1 (en) | 2015-06-17 | 2016-12-22 | Pfizer Inc. | Tricyclic compounds and their use as phosphodiesterase inhibitors |
WO2016207240A1 (en) | 2015-06-24 | 2016-12-29 | F. Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies with tailored affinity |
KR102161364B1 (ko) | 2015-09-14 | 2020-09-29 | 화이자 인코포레이티드 | LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체 |
JP2018531924A (ja) | 2015-09-24 | 2018-11-01 | ファイザー・インク | テトラヒドロピラノ[3,4−d][1,3]オキサジン誘導体、およびbace阻害剤としてのその使用 |
AU2016325665A1 (en) | 2015-09-24 | 2018-03-08 | Pfizer Inc. | N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides |
JP2018534251A (ja) | 2015-09-24 | 2018-11-22 | ファイザー・インク | Bace阻害剤として有用なn−[2−(3−アミノ−2,5−ジメチル−1,1−ジオキシド−5,6−ジヒドロ−2h−1,2,4−チアジアジン−5−イル)−1,3−チアゾール−4−イル]アミド |
JP6657392B2 (ja) | 2015-10-02 | 2020-03-04 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性抗ヒトcd20/ヒトトランスフェリン受容体抗体及び使用方法 |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
US10759837B2 (en) * | 2015-11-09 | 2020-09-01 | The University Of British Columbia | Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide |
WO2017079831A1 (en) | 2015-11-09 | 2017-05-18 | The University Of British Columbia | N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto |
CN108350052A (zh) * | 2015-11-09 | 2018-07-31 | 英属哥伦比亚大学 | 淀粉样蛋白β中间区域中的表位及其构象选择性抗体 |
KR102148587B1 (ko) | 2016-02-23 | 2020-08-26 | 화이자 인코포레이티드 | 6,7-디히드로-5H-피라졸로[5,1-b][1,3]옥사진-2-카르복스아미드 화합물 |
HUE054857T2 (hu) | 2016-07-01 | 2021-10-28 | Pfizer | 5,7-dihidro-pirrolo-piridinszármazékok neurológiai és neurodegeneratív betegségek kezelésére |
AU2017321782B2 (en) | 2016-08-31 | 2022-03-10 | The General Hospital Corporation | Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases |
US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
KR102567845B1 (ko) | 2017-01-31 | 2023-08-17 | 화이자 인코포레이티드 | 네이세리아 메닌기티디스 조성물 및 그의 방법 |
WO2018163030A1 (en) | 2017-03-10 | 2018-09-13 | Pfizer Inc. | Cyclic substituted imidazo[4,5-c]quinoline derivatives |
JP7219223B2 (ja) | 2017-03-10 | 2023-02-07 | ファイザー・インク | LRRK2阻害剤としての新規のイミダゾ[4,5-c]キノリン誘導体 |
RU2678987C2 (ru) | 2017-04-28 | 2019-02-05 | Общество с ограниченной ответственностью "Научно-производственная фирма ВЕРТА" | Пептид для лечения болезни альцгеймера |
EP3634978A1 (de) | 2017-06-07 | 2020-04-15 | Adrx, Inc. | Tau-aggregationshemmer |
EP3642202B1 (de) | 2017-06-22 | 2022-11-02 | Pfizer Inc. | Dihydro-pyrrolo-pyrimidinderivate |
US11209638B2 (en) * | 2017-07-05 | 2021-12-28 | West Virginia University | Systems and methods for supporting and positioning body tissue samples in a microscope |
EP3654946A4 (de) | 2017-07-20 | 2021-04-21 | AZTherapies, Inc. | Pulverförmige formulierungen von cromolyn-natrium und ibuprofen |
CA3073062A1 (en) | 2017-08-18 | 2019-02-21 | Adrx, Inc. | Tau aggregation peptide inhibitors |
SG11202001281WA (en) | 2017-08-22 | 2020-03-30 | Biogen Ma Inc | Pharmaceutical compositions containing anti-beta amyloid antibodies |
DK3461819T3 (da) | 2017-09-29 | 2020-08-10 | Probiodrug Ag | Inhibitorer af glutaminylcyklase |
DK3768669T3 (da) | 2018-03-23 | 2023-04-24 | Pfizer | Piperazinazaspiroderivater |
US12018069B2 (en) | 2018-06-28 | 2024-06-25 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for imaging amyloid deposits |
CA3105392A1 (en) | 2018-07-02 | 2020-01-09 | The General Hospital Corporation | Powdered formulations of cromolyn sodium and .alpha.-lactose |
WO2021236809A2 (en) | 2020-05-19 | 2021-11-25 | Othair Prothena Limited | Multi-epitope vaccine for the treatment of alzheimer's disease |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0683234A1 (de) * | 1993-01-25 | 1995-11-22 | Takeda Chemical Industries, Ltd. | ANTIKÖRPER GEGEN -g(b)-AMYLOID ODER DERIVATE DAVON UND SEINE VERWENDUNG |
EP0526511B1 (de) * | 1990-04-27 | 1997-05-28 | MCMICHAEL, John | Verfahren und zusammensetzung zur behandlung von erkrankungen des zns hervorgerufen durch abnormales beta-amyloid-protein |
Family Cites Families (431)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US589566A (en) * | 1897-09-07 | meevten | ||
US6096318A (en) | 1973-05-07 | 2000-08-01 | The Ohio State University | Antigenically modified HCG polypeptides |
JPS57212347A (en) * | 1981-06-25 | 1982-12-27 | Nissan Motor Co Ltd | Air-fuel ratio control system |
US4902506A (en) * | 1983-07-05 | 1990-02-20 | The University Of Rochester | Immunogenic conjugates |
GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5158769A (en) * | 1984-03-07 | 1992-10-27 | New York Blood Center, Inc. | Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers |
US5417986A (en) * | 1984-03-16 | 1995-05-23 | The United States Of America As Represented By The Secretary Of The Army | Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres |
US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4666829A (en) | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
IT1190383B (it) * | 1985-08-01 | 1988-02-16 | Eniricerche Spa | Sostanze peptidominetiche ad azione ipotensiva |
DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US4713366A (en) * | 1985-12-04 | 1987-12-15 | The Ohio State University Research Foundation | Antigenic modification of polypeptides |
US5096706A (en) * | 1986-03-25 | 1992-03-17 | National Research Development Corporation | Antigen-based treatment for adiposity |
US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US6548640B1 (en) * | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US5278049A (en) * | 1986-06-03 | 1994-01-11 | Incyte Pharmaceuticals, Inc. | Recombinant molecule encoding human protease nexin |
US5231170A (en) * | 1986-08-27 | 1993-07-27 | Paul Averback | Antibodies to dense microspheres |
US5223482A (en) | 1986-11-17 | 1993-06-29 | Scios Nova Inc. | Recombinant Alzheimer's protease inhibitory amyloid protein and method of use |
US5187153A (en) | 1986-11-17 | 1993-02-16 | Scios Nova Inc. | Methods of treatment using Alzheimer's amyloid polypeptide derivatives |
US5220013A (en) * | 1986-11-17 | 1993-06-15 | Scios Nova Inc. | DNA sequence useful for the detection of Alzheimer's disease |
US4879213A (en) | 1986-12-05 | 1989-11-07 | Scripps Clinic And Research Foundation | Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse |
US4818397A (en) * | 1986-12-22 | 1989-04-04 | Sundstrand Corporation | Shut-off valve seal |
DE3702789A1 (de) | 1987-01-30 | 1988-08-18 | Bayer Ag | Vorlaeuferprotein des apc-polypeptids, dafuer codierende dna und diagnostische verwendung der dna und des proteins |
US4912206A (en) * | 1987-02-26 | 1990-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | CDNA clone encoding brain amyloid of alzheimer's disease |
JP3101690B2 (ja) * | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
US4883666A (en) | 1987-04-29 | 1989-11-28 | Massachusetts Institute Of Technology | Controlled drug delivery system for treatment of neural disorders |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5583112A (en) | 1987-05-29 | 1996-12-10 | Cambridge Biotech Corporation | Saponin-antigen conjugates and the use thereof |
US5245015A (en) | 1991-04-26 | 1993-09-14 | Tanox Biosystems, Inc. | Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US5641474A (en) * | 1987-06-24 | 1997-06-24 | Autoimmune, Inc. | Prevention of autoimmune diseases by aerosol administration of autoantigens |
US5645820A (en) * | 1987-06-24 | 1997-07-08 | Autoimmune, Inc. | Treatment of autoimmune diseases by aerosol administration of autoantigens |
US5869054A (en) * | 1987-06-24 | 1999-02-09 | Autoimmune Inc. | Treatment of multiple sclerosis by oral administration of autoantigens |
US5571500A (en) * | 1987-06-24 | 1996-11-05 | Autoimmune, Inc. | Treatment of autoimmune diseases through administration by inhalation of autoantigens |
US5849298A (en) * | 1987-06-24 | 1998-12-15 | Autoimmune Inc. | Treatment of multiple sclerosis by oral administration of bovine myelin |
US5571499A (en) * | 1987-06-24 | 1996-11-05 | Autoimmune, Inc. | Treatment of autoimmune diseases by aerosol administration of autoantigens |
EP0666080B1 (de) | 1987-06-24 | 2004-01-21 | Brigham & Women's Hospital | Behandlung von Autoimmun-Erkrankungen durch orale Verabreichung von Autoantigenen |
US4912208A (en) * | 1987-06-29 | 1990-03-27 | Abbott Laboratories | Fluorophores for encapsulation into liposomes |
US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
US4966753A (en) | 1987-08-18 | 1990-10-30 | Molecular Rx, Inc. | Immunotherapeutic methods and compositions employing antigens characteristic of malignant neoplasms |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
US5231000A (en) * | 1987-10-08 | 1993-07-27 | The Mclean Hospital | Antibodies to A4 amyloid peptide |
CA1339014C (en) | 1987-10-08 | 1997-03-25 | Ronald E. Majocha | Antibodies to a4 amyloid peptide |
WO1989003687A1 (en) | 1987-10-23 | 1989-05-05 | Genetics Institute, Inc. | Composition and method for treating cancers characterized by over-expression of the c-fms proto-oncogene |
US5089603A (en) | 1989-06-21 | 1992-02-18 | Tanox Biosystems, Inc. | Antigenic epitopes present on membrane-bound but not secreted iga |
WO1989006689A1 (en) | 1988-01-13 | 1989-07-27 | The Mclean Hospital Corporation | Genetic constructs containing the alzheimer brain amyloid gene |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
US5576184A (en) * | 1988-09-06 | 1996-11-19 | Xoma Corporation | Production of chimeric mouse-human antibodies with specificity to human tumor antigens |
US5098706A (en) * | 1988-11-01 | 1992-03-24 | The Regents Of The University Of California | Juvenile hormone esterase for insect control |
WO1990005142A1 (en) | 1988-11-10 | 1990-05-17 | Imperial Cancer Research Technology Ltd. | Polypeptides |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5227159A (en) | 1989-01-31 | 1993-07-13 | Miller Richard A | Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies |
US5262332A (en) | 1989-04-05 | 1993-11-16 | Brigham And Women's Hospital | Diagnostic method for Alzheimer's disease: examination of non-neural tissue |
AU5439790A (en) | 1989-04-14 | 1990-11-16 | Research Foundation For Mental Hygiene, Inc. | Cerebrovascular amyloid protein-specific monoclonal antibody sv17-6e10 |
AU5525090A (en) | 1989-04-14 | 1990-11-16 | Research Foundation For Mental Hygiene, Inc. | Monoclonal antibody to amyloid peptide |
WO1990014837A1 (en) | 1989-05-25 | 1990-12-13 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
HUT61487A (en) | 1989-12-20 | 1993-01-28 | Brigham & Womens Hospital | Process for producing aerosol pharmaceutical composition comprising autoantigens |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
EP0594607B1 (de) | 1990-03-02 | 1997-08-27 | Autoimmune, Inc. | Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen |
GB9005705D0 (en) | 1990-03-14 | 1990-05-09 | Health Lab Service Board | Particle manipulation |
US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
EP0451700A1 (de) | 1990-04-10 | 1991-10-16 | Miles Inc. | Rekombinante APP Minigene zur Expression in Transgen-Mäusen als Alzheimer-Krankheitsmuster |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
JPH05506990A (ja) | 1990-04-24 | 1993-10-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | プロテアーゼ ネキシン―2の精製、検出、及び使用方法 |
GB9009548D0 (en) | 1990-04-27 | 1990-06-20 | Celltech Ltd | Chimeric antibody and method |
US5753624A (en) * | 1990-04-27 | 1998-05-19 | Milkhaus Laboratory, Inc. | Materials and methods for treatment of plaquing disease |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
WO1991018980A1 (en) | 1990-06-01 | 1991-12-12 | Cetus Corporation | Compositions and methods for identifying biologically active molecules |
AU646877B2 (en) | 1990-06-15 | 1994-03-10 | Scios Nova Inc. | Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease |
US5914109A (en) * | 1990-06-15 | 1999-06-22 | New York University | Heterohybridomas producing human monoclonal antibodies to HIV-1 |
CA2085897A1 (en) | 1990-06-19 | 1991-12-20 | George Pieczenik | Nonpathogenic variant virus |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
KR970005049B1 (ko) * | 1990-07-16 | 1997-04-11 | 더 리젠츠 오브 더 유니벌시티 오브 캘리포니아 | 바쿨로비루스 발현 시스템, 이 벡터 시스템을 포함하는 이종성 무척추동물 숙주세포, 상기 시스템에 의해 생산되는 가용성의 정제된 야생형 망막아세포종 폴리펩티드 및 이 폴리펩티드의 생산 방법 |
US5780587A (en) * | 1990-08-24 | 1998-07-14 | President And Fellows Of Harvard College | Compounds and methods for inhibiting β-protein filament formation and neurotoxicity |
NZ239643A (en) | 1990-09-17 | 1996-05-28 | North American Vaccine Inc | Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group. |
US5702906A (en) | 1990-09-25 | 1997-12-30 | Genentech, Inc. | Antibodies to neurotrophic factor-4 (NT-4) |
JPH06502071A (ja) | 1990-09-28 | 1994-03-10 | ジ・アップジョン・カンパニー | アルツハイマーのアミロイド前駆遺伝子を有するトランスジェニック動物 |
JP3583420B2 (ja) * | 1990-10-05 | 2004-11-04 | メダレツクス・インコーポレーテツド | 二特異的試薬を用いた標的免疫化 |
HUT69942A (en) | 1990-10-15 | 1995-09-28 | Brigham & Womens Hospital | Treatment of autoimmun diseases by oral administration of autoantigenes |
GB9023352D0 (en) | 1990-10-26 | 1990-12-05 | Lynxvale Ltd | Vaccinia vectors,vaccinia genes and expression products thereof |
DE971033T1 (de) | 1991-01-21 | 2001-05-03 | Imperial College Of Science, Technology & Medicine | Prüfung und Modell für Alzheimers-Krankheit |
ES2149166T3 (es) | 1991-03-01 | 2000-11-01 | Merial Sas | Procedimiento de inmunoneutralizacion anti-lhrm de los animales domesticos machos no castrados y peptido para su realizacion. |
DE4107857A1 (de) * | 1991-03-12 | 1992-09-17 | Thomae Gmbh Dr K | Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
US5192753A (en) * | 1991-04-23 | 1993-03-09 | Mcgeer Patrick L | Anti-rheumatoid arthritic drugs in the treatment of dementia |
DE69229703T2 (de) | 1991-05-08 | 2000-04-27 | Schweiz Serum & Impfinst | Wiederhergestellte Influenza-Virosomen mit immunostimulierenden und immunoverstärkenden Eigenschaften und diese enthaltende Impfstoffe |
WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
US5672805A (en) | 1991-07-18 | 1997-09-30 | The Regents Of The University Of California | Transgenic mice expressing the neurotoxic C-terminus of β-amyloid precursor protein |
US5434050A (en) | 1991-08-13 | 1995-07-18 | Regents Of The University Of Minnesota | Labelled β-amyloid peptide and methods of screening for Alzheimer's disease |
US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
EP0773227A1 (de) | 1991-09-18 | 1997-05-14 | Affymax Technologies N.V. | Verschiedene Sammlungen von Oligomeren, zum Verfahren zur Herstellung von Arzneimitteln, Diagnostische-Reagenzen, Schädlingsbekämpfungsmitteln und Herbiziden |
US5837268A (en) | 1991-10-16 | 1998-11-17 | University Of Saskatchewan | GnRH-leukotoxin chimeras |
AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
CA2127450C (en) | 1992-01-07 | 2007-04-17 | Samuel Wadsworth | Transgenic animal models for alzheimer's disease |
US5679348A (en) * | 1992-02-03 | 1997-10-21 | Cedars-Sinai Medical Center | Immunotherapy for recurrent HSV infections |
ES2204900T3 (es) | 1992-02-11 | 2004-05-01 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Estructura inmuinogena de doble vector. |
US5314813A (en) | 1992-02-19 | 1994-05-24 | Scripps Research Institute | Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines |
KR950700082A (ko) | 1992-02-28 | 1995-01-16 | 로버트 씨. 비숍 | 바이스탠더(bystander)에 의한 자가면역질환을 처치하는 방법 |
US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
EP0561087B1 (de) | 1992-03-20 | 1999-08-04 | N.V. Innogenetics S.A. | Mutierte Form von dem Beta-Amyloidprecursor Proteine Gen |
US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
US5441870A (en) * | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
US5851787A (en) * | 1992-04-20 | 1998-12-22 | The General Hospital Corporation | Nucleic acid encoding amyloid precursor-like protein and uses thereof |
AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
GB9209118D0 (en) | 1992-04-28 | 1992-06-10 | Sb 120 Amsterdam Bv | Vaccine compositions |
DK0652758T3 (da) | 1992-06-18 | 2000-05-08 | Harvard College | Diferitoxin-vacciner |
CA2138997C (en) * | 1992-06-25 | 2003-06-03 | Jean-Paul Prieels | Vaccine composition containing adjuvants |
US5837672A (en) * | 1992-07-10 | 1998-11-17 | Athena Neurosciences, Inc. | Methods and compositions for the detection of soluble β-amyloid peptide |
US5766846A (en) * | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
US6610493B1 (en) | 1993-06-17 | 2003-08-26 | Brigham And Women's Hospital | Screening compounds for the ability to alter the production of amyloid-β peptide |
WO1994001772A1 (en) | 1992-07-13 | 1994-01-20 | The Children's Medical Center Corporation | SCREEN FOR ALZHEIMER'S DISEASE THERAPEUTICS BASED ON β-AMYLOID PRODUCTION |
IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
DE69322645T2 (de) | 1992-07-31 | 1999-05-20 | Medeva Holdings B.V., Amsterdam | Expression rekombinanter fusionsproteine in attenuierten bakterien |
NZ255256A (en) | 1992-08-27 | 1997-02-24 | Deakin Res Ltd | Synthetic peptide antigen analogues with retro, inverso or retro-inverso modification, their use and antibodies against them |
FI96267C (sv) | 1992-09-16 | 1996-06-10 | Formit Foodprocessing Ab Oy | Vals och maskin för skalning eller formning av potatis och liknande produkter |
US5958883A (en) * | 1992-09-23 | 1999-09-28 | Board Of Regents Of The University Of Washington Office Of Technology | Animal models of human amyloidoses |
US5414548A (en) * | 1992-09-29 | 1995-05-09 | Nippon Telegraph And Telephone Corporation | Arrayed-wave guide grating multi/demultiplexer with loop-back optical paths |
DK0665897T3 (da) | 1992-10-01 | 2003-10-20 | Univ Columbia | Komplekse, kombinatoriske, kemiske biblioteker kodet med etiketter |
WO1994009364A1 (en) | 1992-10-13 | 1994-04-28 | Duke University | Method of inhibiting binding of amyloid precursor protein to beta-amyloid protein |
US5605811A (en) * | 1992-10-26 | 1997-02-25 | Athena Neurosciences, Inc. | Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein |
PT1298436E (pt) | 1992-10-26 | 2010-10-21 | Lilly Co Eli | Métodos para a identificação de compostos inibidores da libertação de péptido beta-amilóide (bap) |
US5972336A (en) * | 1992-11-03 | 1999-10-26 | Oravax Merieux Co. | Urease-based vaccine against helicobacter infection |
US5733647A (en) * | 1992-11-05 | 1998-03-31 | Polymer Innovations, Inc. | Insole |
US6210671B1 (en) * | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
US5674703A (en) | 1992-12-02 | 1997-10-07 | Woo; Savio L. C. | Episomal vector systems and related methods |
ES2196024T3 (es) | 1993-01-22 | 2003-12-16 | Sloan Kettering Inst Cancer | Vacunas conjugadas de gangliosido-klh con qs-21. |
US5955317A (en) * | 1993-01-25 | 1999-09-21 | Takeda Chemical Industries, Ltd. | Antibodies to β-amyloids or their derivatives and use thereof |
US5750106A (en) * | 1993-01-28 | 1998-05-12 | Novartis Ag | Human monoclonal antibodies to cytomegalovirus |
US5989565A (en) * | 1993-01-29 | 1999-11-23 | University Of Pittsburgh | Elution and identification of T cell epitopes from viable cells |
US5358708A (en) | 1993-01-29 | 1994-10-25 | Schering Corporation | Stabilization of protein formulations |
US5472693A (en) | 1993-02-16 | 1995-12-05 | The Dow Chemical Company | Family of anti-carcinoembryonic antigen chimeric antibodies |
DE614989T1 (de) * | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
CA2115900A1 (en) | 1993-02-22 | 1994-08-23 | Gerald W. Becker | Pharmaceutical screens and antibodies |
WO1994021680A1 (en) * | 1993-03-17 | 1994-09-29 | The Government Of The United States Of America As | Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments |
WO1994021288A1 (en) | 1993-03-18 | 1994-09-29 | Cytimmune Sciences, Inc. | Composition and method for reducing toxicity of biologically-active factors |
EP1175912A1 (de) * | 1993-03-23 | 2002-01-30 | SmithKline Beecham Biologics SA | 3-0-deazylierte Monophosphoryl Lipid A enthaltende Impfstoff-Zusammensetzungen |
CA2119090A1 (en) * | 1993-03-26 | 1994-09-27 | Wayne R. Gombotz | Compositions for controlled release of biologically active tgf-.beta. |
IT1270939B (it) | 1993-05-11 | 1997-05-26 | Angeletti P Ist Richerche Bio | Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili. |
DK0705109T4 (da) | 1993-05-25 | 2004-05-10 | Wyeth Corp | Adjuvanser til vacciner mod respiratorisk syncytialvirus |
AU7043894A (en) | 1993-05-28 | 1994-12-20 | Miriam Hospital, The | Composition and method for (in vivo) imaging of amyloid deposits |
CA2164298A1 (en) | 1993-06-04 | 1994-12-22 | Richard A. Young | Stress proteins and uses therefor |
US5464823A (en) * | 1993-07-20 | 1995-11-07 | The Regents Of The University Of California | Mammalian antibiotic peptides |
CA2168459C (en) | 1993-07-30 | 2002-10-01 | Mohammed Anjam Khan | Fusion proteins containing the c-terminal of tetanus toxin linked to a heterologous protein |
CA2146667A1 (en) | 1993-08-18 | 1995-02-23 | Adolf Hoess | Lipopolysaccharide-binding and neutralizing peptides |
AU705889B2 (en) | 1993-08-26 | 1999-06-03 | Regents Of The University Of California, The | Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory peptides |
AU707083B2 (en) | 1993-08-26 | 1999-07-01 | Bavarian Nordic Inc. | Inducing antibody response against self-proteins with the aid of foreign T-cell epitopes |
DK96493D0 (da) | 1993-08-26 | 1993-08-26 | Mouritsen Og Elsner Aps | Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden |
FR2709247B1 (fr) * | 1993-08-27 | 1995-09-29 | Martin Jean Raymond | Dispositif d'ancrage d'une instrumentation rachidienne sur une vertèbre. |
WO1995006407A1 (en) | 1993-08-30 | 1995-03-09 | The Regents Of The University Of California | Novel component of amyloid in alzheimer's disease and methods for use of same |
UA48940C2 (uk) | 1993-09-07 | 2002-09-16 | Смітклайн Бічам Корпорейшн | Рекомбінатні il4 антитіла, які використовуються для лікування il4-опосередкованих порушень |
US5652334A (en) * | 1993-09-08 | 1997-07-29 | City Of Hope | Method for design of substances that enhance memory and improve the quality of life |
US5385887A (en) * | 1993-09-10 | 1995-01-31 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
AU698962B2 (en) | 1993-09-14 | 1998-11-12 | Epimmune, Inc. | Alteration of immune response using pan DR-binding peptides |
US5415584A (en) | 1993-09-21 | 1995-05-16 | Tomco2 Equipment Company | Particle blast cleaning apparatus |
US5470951A (en) * | 1993-09-29 | 1995-11-28 | City Of Hope | Peptides for antagonizing the effects of amyloid βprotein |
US5858981A (en) | 1993-09-30 | 1999-01-12 | University Of Pennsylvania | Method of inhibiting phagocytosis |
DE69429925T2 (de) | 1993-10-20 | 2002-10-02 | Duke University, Durham | METHODE ZUR BINDUNG VON MATERIAL AN DAS Beta-AMYLOID-PEPTID |
ES2182850T3 (es) | 1993-10-22 | 2003-03-16 | Genentech Inc | Procedimientos y composiciones para la microencapsulacion de adyuvantes. |
BR9407947A (pt) | 1993-11-02 | 1996-11-26 | Affymax Tech Nv | Processo para sintetizar moléculas diversas em uma pluralidade de substratos e uma coleçao molecular etiquetade para realizaçao reaçoes de copulaçao em contas em paralelo para triar uma coleçao molecular etiquetada para detectar a presença de um ou mais diferentes etiquetas e para determinar a sequência de síntese aparelho para reaçoes de copulaçao paralelas em suportes sólidos bloco de alinhamento ótico para uso com um detector ótico sistemas de distribuiçao para distribuir reagentes dispositiv |
US5744368A (en) | 1993-11-04 | 1998-04-28 | Research Foundation Of State University Of New York | Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR) |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US5434170A (en) * | 1993-12-23 | 1995-07-18 | Andrulis Pharmaceuticals Corp. | Method for treating neurocognitive disorders |
WO1995020666A2 (en) * | 1994-01-27 | 1995-08-03 | Regents Of The University Of Minnesota | Transgenic non-human mammals with progressive neurologic disease |
US5877399A (en) * | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
US5935927A (en) * | 1994-02-03 | 1999-08-10 | The Picower Institute For Medical Research | Compositions and methods for stimulating amyloid removal in amyloidogenic diseases using advanced glycosylation endproducts |
AUPM411994A0 (en) | 1994-02-25 | 1994-03-24 | Deakin Research Limited | Epitopes |
CN1069667C (zh) | 1994-02-28 | 2001-08-15 | 住友化学工业株式会社 | 聚烯烃系树脂组合物及树脂薄膜 |
US5795954A (en) | 1994-03-04 | 1998-08-18 | Genentech, Inc. | Factor VIIa inhibitors from Kunitz domain proteins |
US6270757B1 (en) | 1994-04-21 | 2001-08-07 | Genetics Institute, Inc. | Formulations for IL-11 |
US6372716B1 (en) * | 1994-04-26 | 2002-04-16 | Genetics Institute, Inc. | Formulations for factor IX |
CA2189634A1 (en) | 1994-05-06 | 1995-11-16 | John J. Baldwin | Combinatorial dihydrobenzopyran library |
WO1995031996A1 (en) | 1994-05-25 | 1995-11-30 | Milkhaus Lab | Materials and methods for treatment of plaquing diseases |
US5622701A (en) * | 1994-06-14 | 1997-04-22 | Protein Design Labs, Inc. | Cross-reacting monoclonal antibodies specific for E- and P-selectin |
US5663046A (en) | 1994-06-22 | 1997-09-02 | Pharmacopeia, Inc. | Synthesis of combinatorial libraries |
US5798100A (en) * | 1994-07-06 | 1998-08-25 | Immunomedics, Inc. | Multi-stage cascade boosting vaccine |
US6417178B1 (en) * | 1994-07-19 | 2002-07-09 | University Of Pittsburgh | Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits |
EP0769963A4 (de) | 1994-07-27 | 1999-07-28 | Commw Scient Ind Res Org | Polyepitope impfstoffe |
PT784684E (pt) | 1994-09-16 | 2007-11-23 | Cancer Res Fund Of Contra Cost | ''péptidos recontinantes derivados do anticorpo mc3 anti-ba46, métodos para a sua utilização e métodos de hmnanização de péptidos do anticorpo'' |
ATE178104T1 (de) * | 1994-10-14 | 1999-04-15 | Oriental Sangyo Co Ltd | Elektrolytische vorrichtung zur herstellung von kohlenstoff-dioxyd |
NL9401735A (nl) * | 1994-10-19 | 1996-06-03 | Crown Gear Bv | Tandwieloverbrenging van een cilindrisch rondsel met een kroonwiel, het kroonwiel dat toegepast wordt in deze tandwieloverbrenging, een werkwijze volgens welke het kroonwiel gemaakt kan worden alsmede een gereedschap waarmee het kroonwiel gemaakt kan worden. |
US5872005A (en) * | 1994-11-03 | 1999-02-16 | Cell Genesys Inc. | Packaging cell lines for adeno-associated viral vectors |
JPH08137927A (ja) * | 1994-11-07 | 1996-05-31 | Hitachi Ltd | 部品配置配線表示方法 |
US6114133A (en) * | 1994-11-14 | 2000-09-05 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41) |
US5589154A (en) | 1994-11-22 | 1996-12-31 | Rutgers, The State University Of New Jersey | Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease |
US5688651A (en) | 1994-12-16 | 1997-11-18 | Ramot University Authority For Applied Research And Development Ltd. | Prevention of protein aggregation |
JP2000510813A (ja) * | 1995-02-06 | 2000-08-22 | ジェネテイックス・インスティテュート・インコーポレイテッド | Il−12用処方 |
US5786180A (en) | 1995-02-14 | 1998-07-28 | Bayer Corporation | Monoclonal antibody 369.2B specific for β A4 peptide |
US5624937A (en) | 1995-03-02 | 1997-04-29 | Eli Lilly And Company | Chemical compounds as inhibitors of amyloid beta protein production |
US5817626A (en) * | 1995-03-14 | 1998-10-06 | Praecis Pharmaceuticals Incorporated | Modulators of beta-amyloid peptide aggregation |
US6303567B1 (en) * | 1995-03-14 | 2001-10-16 | Praecis Pharmaceuticals, Inc . | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
US5854215A (en) | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals Incorporated | Modulators of β-amyloid peptide aggregation |
WO1996028471A1 (en) | 1995-03-14 | 1996-09-19 | Praecis Pharmaceuticals Incorporated | Modulators of amyloid aggregation |
JPH11502222A (ja) * | 1995-03-23 | 1999-02-23 | キャンタブ ファーマシューティカルズ リサーチ リミティド | 遺伝子供給用ベクター |
US5869046A (en) * | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
DE69633175T2 (de) | 1995-05-23 | 2005-08-11 | Morphosys Ag | Multimere proteine |
WO1996039176A1 (en) | 1995-06-05 | 1996-12-12 | Brigham & Women's Hospital | USE OF ORAL TOLERANCE TO SUPPRESS BOTH Th1 AND Th2 IMMUNE RESPONSES AND TO SUPPRESS ANTIBODY PRODUCTION |
US5948763A (en) | 1995-06-07 | 1999-09-07 | New York University | Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits |
CA2221986A1 (en) | 1995-06-07 | 1996-12-19 | Athena Neurosciences, Inc. | Method for identifying alzheimer's disease therapeutics using transgenic animal models |
IT1276680B1 (it) * | 1995-06-08 | 1997-11-03 | Oris Spa | Processo di sintesi dell'1-piridiniopropan-3-solfonato |
US5910427A (en) | 1995-06-22 | 1999-06-08 | La Jolla Institute For Allergy And Immunology | Antigen non-specific glycosylation inhibiting factor derivatives |
US5780361A (en) * | 1995-06-23 | 1998-07-14 | Nec Corporation | Salicide process for selectively forming a monocobalt disilicide film on a silicon region |
SI0750907T1 (en) * | 1995-06-30 | 2002-08-31 | American Cyanamid Company | Stable macrolide and macrolide vaccine compositions |
EP1637600A1 (de) * | 1995-07-07 | 2006-03-22 | Darwin Molecular Corporation | Auf Chromosom 1 lokalisiertes Gen und mit der Alzheimerschen Krankheit assoziierte Genprodukte |
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
AUPN443995A0 (en) | 1995-07-27 | 1995-08-17 | Csl Limited | Papillomavirus polyprotein |
PT859841E (pt) | 1995-08-18 | 2002-11-29 | Morphosys Ag | Bibliotecas de proteinas/ (poli) peptidos |
WO1997006809A1 (en) * | 1995-08-21 | 1997-02-27 | Cytrx Corporation | Compositions and methods for growth promotion |
BR9610580A (pt) | 1995-09-14 | 2000-10-24 | Univ California | Anticorpos especìficos para prpse nativos |
US5664823A (en) * | 1995-09-18 | 1997-09-09 | Ford Global Technologies, Inc. | Instrument panel brace |
US5731284A (en) | 1995-09-28 | 1998-03-24 | Amgen Inc. | Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product |
EP0854919A1 (de) | 1995-10-10 | 1998-07-29 | Novartis AG | Melanoma-assoziiertes protein |
US5985242A (en) * | 1995-10-27 | 1999-11-16 | Praecis Pharmaceuticals, Inc. | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
US5750361A (en) * | 1995-11-02 | 1998-05-12 | The Regents Of The University Of California | Formation and use of prion protein (PRP) complexes |
NZ322175A (en) | 1995-11-10 | 1999-02-25 | Elan Corp Plc | Peptides which enhance transport across tissues and methods of identifying the same |
WO1997018855A1 (en) | 1995-11-21 | 1997-05-29 | Eduard Naumovich Lerner | Device for enhanced delivery of biologically active substances and compounds in an organism |
EP0866805A1 (de) | 1995-12-12 | 1998-09-30 | Karolinska Innovations AB | Peptide, das die KLVFF Sequenz von beta-Amyloid bindet |
JPH09178743A (ja) | 1995-12-27 | 1997-07-11 | Oriental Yeast Co Ltd | 可溶性appの定量法 |
US6015662A (en) | 1996-01-23 | 2000-01-18 | Abbott Laboratories | Reagents for use as calibrators and controls |
ZA97452B (en) | 1996-01-25 | 1997-08-15 | Trinity College Dublin | Streptococcus equi vaccine. |
US5770700A (en) | 1996-01-25 | 1998-06-23 | Genetics Institute, Inc. | Liquid factor IX formulations |
WO1997026913A1 (en) | 1996-01-26 | 1997-07-31 | The Trustees Of Columbia University In The City Of New York | A POLYPEPTIDE FROM LUNG EXTRACT WHICH BINDS AMYLOID-β PEPTIDE |
GB9602294D0 (en) * | 1996-02-05 | 1996-04-03 | Zeneca Ltd | Heterocyclic compounds |
US6096313A (en) | 1996-02-09 | 2000-08-01 | Ludwig Institute For Cancer Research | Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant |
WO1997032017A1 (en) | 1996-02-26 | 1997-09-04 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Novel method for the identification of nucleic acid sequences encoding two or more interacting (poly)peptides |
US6150091A (en) * | 1996-03-06 | 2000-11-21 | Baylor College Of Medicine | Direct molecular diagnosis of Friedreich ataxia |
US5870587A (en) * | 1996-03-20 | 1999-02-09 | International Business Machines Corporation | Information-handling system, method, and article of manufacture including a mechanism for providing an improved application binary interface |
CA2216425C (en) | 1996-03-23 | 2003-08-12 | The Research Foundation For Microbial Diseases Of Osaka University | Tetanus toxin functional fragment antigen and tetanus vaccine |
WO1997037031A1 (en) * | 1996-03-29 | 1997-10-09 | University Of Otago | Parapoxvirus vectors |
WO1997036601A1 (en) * | 1996-04-03 | 1997-10-09 | Anergen, Inc. | Cyclic peptide vaccines for treatment and prevention of diabetes |
AU735733B2 (en) * | 1996-04-19 | 2001-07-12 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Antigenically reactive regions of the hepatitis A virus polyprotein |
US6284533B1 (en) * | 1996-05-01 | 2001-09-04 | Avant Immunotherapeutics, Inc. | Plasmid-based vaccine for treating atherosclerosis |
DE69726003T2 (de) | 1996-07-16 | 2004-08-26 | Andreas Plückthun | Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit |
JP2000516090A (ja) | 1996-07-26 | 2000-12-05 | スローン―ケッタリング インスティチュート フォー キャンサー リサーチ | 遺伝子的免疫化のための方法と試薬 |
US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
GB9617616D0 (en) | 1996-08-22 | 1996-10-02 | Osteometer Biotech As | Assaying protein fragments in body fluids |
CA2183901A1 (en) | 1996-08-22 | 1998-02-23 | Johanna E. Bergmann | Targets for therapy and diagnosis of alzheimer's disease and down syndrome in humans |
DE69733655T2 (de) | 1996-08-27 | 2006-04-27 | Praecis Pharmaceuticals, Inc., Cambridge | beta-AMYLOID PEPTIDAGGREGATION REGULIERENDE PEPTIDE MIT D-AMINOSÄUREN |
US6057367A (en) * | 1996-08-30 | 2000-05-02 | Duke University | Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses |
US6797495B2 (en) * | 1996-11-05 | 2004-09-28 | The Regents Of The University Of California | Somatic cells with ablated PrP gene and methods of use |
US6022859A (en) * | 1996-11-15 | 2000-02-08 | Wisconsin Alumni Research Foundation | Inhibitors of β-amyloid toxicity |
AU5508798A (en) | 1996-11-19 | 1998-06-10 | Trustees Of The University Of Pennsylvania, The | Diagnostic and therapeutic reagents for alzheimer's disease |
US6962984B2 (en) | 1996-12-05 | 2005-11-08 | Nihon University | IgA nephropathy-related DNA |
US6218506B1 (en) | 1997-02-05 | 2001-04-17 | Northwestern University | Amyloid β protein (globular assembly and uses thereof) |
US20030068316A1 (en) | 1997-02-05 | 2003-04-10 | Klein William L. | Anti-ADDL antibodies and uses thereof |
WO1998039303A1 (en) | 1997-03-03 | 1998-09-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
US6277375B1 (en) * | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US5798102A (en) | 1997-03-04 | 1998-08-25 | Milkhaus Laboratory, Inc. | Treatment of cardiomyopathy |
US6611610B1 (en) * | 1997-04-02 | 2003-08-26 | Gentex Corporation | Vehicle lamp control |
US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
ATE402717T1 (de) | 1997-04-09 | 2008-08-15 | Intellect Neurosciences Inc | Für die termini des beta-amyloids spezifische, rekombinante antikörper, dafür kodierende dna und verfahren zu ihrer verwendung |
US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
US20020086847A1 (en) * | 1997-04-09 | 2002-07-04 | Mindset Biopharmaceuticals (Usa) | Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof |
HRP980203B1 (en) | 1997-04-15 | 2003-04-30 | Ferring Farma Lab | Modified tnf "alpha" molecules, dna encoding such modified tnf "alpha" molecules and vaccines comprising such modified tnf "alpha" molecules and dna |
US6787319B2 (en) * | 1997-04-16 | 2004-09-07 | American Home Products Corp. | β-amyloid peptide-binding proteins and polynucleotides encoding the same |
US5858205A (en) * | 1997-05-13 | 1999-01-12 | Uop Llc | Multizone catalytic reforming process |
CA2301575C (en) * | 1997-05-20 | 2003-12-23 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
CA2292730C (en) | 1997-06-13 | 2008-09-16 | Genentech, Inc. | Stabilized antibody formulation |
WO1999000150A2 (en) | 1997-06-27 | 1999-01-07 | Regents Of The University Of California | Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor |
IT1293511B1 (it) | 1997-07-30 | 1999-03-01 | Gentili Ist Spa | Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati |
DE69842048D1 (de) | 1997-08-01 | 2011-01-27 | Max Planck Gesellschaft | Zusammensetzung und verfahren zum nachweis von krankheiten in zusammenhang mit der bildung von amyloid-ähnlichen fibrillen oder protein-aggregaten |
JP2002501721A (ja) | 1997-08-01 | 2002-01-22 | モルフォシス・アクチェンゲゼルシャフト | 多量体(ポリ)ペプチドコンプレックスのメンバーをコードする核酸配列を同定するための新規方法およびファージ |
ATE435661T1 (de) | 1997-08-29 | 2009-07-15 | Antigenics Inc | Adjuvant qs-21 enthaltende zusammensetzungen mit polysorbate oder cyclodextrin als hilfsmittel |
US6175057B1 (en) * | 1997-10-08 | 2001-01-16 | The Regents Of The University Of California | Transgenic mouse model of alzheimer's disease and cerebral amyloid angiopathy |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US6750324B1 (en) * | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US6923964B1 (en) | 1997-12-02 | 2005-08-02 | Neuralab Limited | Active immunization of AScr for prion disorders |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US6905686B1 (en) * | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
US6913745B1 (en) * | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
US7588766B1 (en) * | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
US6710226B1 (en) * | 1997-12-02 | 2004-03-23 | Neuralab Limited | Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics |
US6761888B1 (en) * | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
AU742970C (en) | 1997-12-03 | 2003-03-20 | Janssen Alzheimer Immunotherapy | Method of suppressing beta-amyloid-related changes in Alzheimer's disease |
NZ504711A (en) | 1997-12-03 | 2002-02-01 | Fujisawa Pharmaceutical Co | Soft-pellet drug and process for the preparation thereof |
FR2777015B3 (fr) | 1998-02-23 | 2000-09-15 | Financ De Biotechnologie | Procede et moyens pour l'obtention de modeles cellulaires et animaux de maladies neurodegeneratives |
US6528624B1 (en) * | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US6194551B1 (en) * | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US20050059802A1 (en) * | 1998-04-07 | 2005-03-17 | Neuralab Ltd | Prevention and treatment of amyloidogenic disease |
US20050059591A1 (en) * | 1998-04-07 | 2005-03-17 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
EP1073464B1 (de) * | 1998-04-28 | 2004-10-06 | Smithkline Beecham Corporation | Monoklonale antikörper mit verringerter immunisierungsfähigkeit |
NO314086B1 (no) | 1998-05-08 | 2003-01-27 | Gemvax As | Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til |
CA2328612A1 (en) | 1998-05-19 | 1999-11-25 | Yeda Research And Development Co., Ltd. | Activated t cells, nervous system-specific antigens and their uses |
US20030147882A1 (en) * | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
NZ507727A (en) | 1998-05-21 | 2003-11-28 | Univ Tennessee Res Foundation | Methods for amyloid removal using anti-amloid antibodies |
US6432710B1 (en) | 1998-05-22 | 2002-08-13 | Isolagen Technologies, Inc. | Compositions for regenerating tissue that has deteriorated, and methods for using such compositions |
US6710228B1 (en) * | 1998-05-29 | 2004-03-23 | Mycogen Corporation | Cotton cells, plants, and seeds genetically engineered to express insecticidal and fungicidal chitin binding proteins (lectins) |
US6727349B1 (en) * | 1998-07-23 | 2004-04-27 | Millennium Pharmaceuticals, Inc. | Recombinant anti-CCR2 antibodies and methods of use therefor |
PT1117421E (pt) | 1998-10-05 | 2004-11-30 | Pharmexa A S | Novos metodos para vacinacao terapeutica |
EP1150688A4 (de) * | 1998-10-19 | 2004-06-16 | Yeda Res & Dev | Behandlung von systemischer lupus erythematodes durch herunterregulierung der autoimmunantwort auf autoantigene |
US7112661B1 (en) | 1998-10-30 | 2006-09-26 | The Research Foundation Of State University Of New York | Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein Ib alpha |
GB2348203B (en) | 1998-11-04 | 2002-06-19 | Imp College Innovations Ltd | Solube beta-forms of prion proteins, methods of preparation and use |
WO2000043049A1 (en) | 1999-01-19 | 2000-07-27 | Pharmacia & Upjohn Company | Gamma-irradiation sterilized polyethylene packaging |
CA2361124A1 (en) | 1999-01-22 | 2000-07-27 | Matthew John During | Vaccine-mediated treatment of neurological disorders |
US7629311B2 (en) | 1999-02-24 | 2009-12-08 | Edward Lewis Tobinick | Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers |
US7282570B2 (en) | 1999-04-20 | 2007-10-16 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
AU4529800A (en) | 1999-05-05 | 2000-11-21 | Neurochem, Inc. | Stereoselective antifibrillogenic peptides and peptidomimetics thereof |
US6787637B1 (en) * | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
AR024558A1 (es) | 1999-06-01 | 2002-10-16 | Neuralab Ltd | Composiciones del peptido a-beta y procesos para producir las mismas |
AU780474B2 (en) * | 1999-06-16 | 2005-03-24 | Boston Biomedical Research Institute Incorporated | Immunological control of beta-amyloid levels in vivo |
WO2001002855A1 (en) | 1999-07-01 | 2001-01-11 | Scios Inc. | Prevention and treatment of amyloid-associated disorders |
HUP0301349A3 (en) | 1999-07-15 | 2005-12-28 | Genetics Inst Llc Cambridge | Formulations for il-11 |
DE60016227T2 (de) | 1999-08-04 | 2005-12-15 | Northwestern University, Evanston | Globularer aufbau vom amyloid-beta- protein und deren verwendungen |
WO2001018169A2 (en) | 1999-09-03 | 2001-03-15 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Agents and compositions and methods for diagnostic and/or treating or preventing plaque forming diseases |
US6294171B2 (en) | 1999-09-14 | 2001-09-25 | Milkhaus Laboratory, Inc. | Methods for treating disease states comprising administration of low levels of antibodies |
US6824780B1 (en) | 1999-10-29 | 2004-11-30 | Genentech, Inc. | Anti-tumor antibody compositions and methods of use |
US20020094335A1 (en) | 1999-11-29 | 2002-07-18 | Robert Chalifour | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases |
JP2004500354A (ja) | 1999-11-29 | 2004-01-08 | ニューロケム インコーポレーティッド | 全d体ペプチドを含む、アルツハイマー病およびアミロイド関連疾患の予防および処置のためのワクチン |
CN1414976A (zh) | 1999-12-08 | 2003-04-30 | 明德塞特生物制药(美国)公司 | 作为免疫原的嵌合肽及其抗体,以及利用嵌合肽或抗体进行免疫的方法 |
US6399314B1 (en) * | 1999-12-29 | 2002-06-04 | American Cyanamid Company | Methods of detection of amyloidogenic proteins |
AU783144B2 (en) | 2000-02-21 | 2005-09-29 | H. Lundbeck A/S | Novel method for down-regulation of amyloid |
WO2001062284A2 (en) | 2000-02-21 | 2001-08-30 | Pharmexa A/S | Novel method for down-regulation of amyloid |
CZ306683B6 (cs) * | 2000-02-24 | 2017-05-03 | Washington University | Léčivo pro prevenci nebo léčení preklinické nebo klinické Alzheimerovy nemoci |
US6294221B1 (en) * | 2000-03-08 | 2001-09-25 | E. I. Du Pont De Nemours And Company | Process for spray-coating with frequent changes between aqueous and non-aqueous coating agents inside a spray-coating chamber |
US6548840B1 (en) * | 2000-04-03 | 2003-04-15 | Hrl Laboratories, Llc | Monolithic temperature compensation scheme for field effect transistor integrated circuits |
CA2404237C (en) | 2000-04-05 | 2010-01-26 | University Of Tennessee Research Corporation | Methods of investigating, diagnosing, and treating amyloidosis |
CA2396762A1 (en) | 2000-04-13 | 2001-10-25 | Corixa Corporation | Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21 |
ATE286072T1 (de) | 2000-05-22 | 2005-01-15 | Univ New York | Synthetische immunogene jedoch nicht amyloidogene peptide, die homolog zu amyloid beta sind und deren verwendung zur induktion einer immunantwort gegen amyloid beta und amyloidaggregate |
CA2414772C (en) * | 2000-07-07 | 2011-06-28 | Jan Naslund | Prevention and treatment of alzheimer's disease |
EP1172378A1 (de) | 2000-07-12 | 2002-01-16 | Richard Dr. Dodel | Menschlische beta-Amyloid Antikörpern und ihre Verwendung zur Behandlung von Alzheimerscher Krankheit |
US20020009445A1 (en) * | 2000-07-12 | 2002-01-24 | Yansheng Du | Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease |
US7199102B2 (en) * | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
US20030092145A1 (en) | 2000-08-24 | 2003-05-15 | Vic Jira | Viral vaccine composition, process, and methods of use |
WO2002021141A2 (en) | 2000-09-06 | 2002-03-14 | Aventis Pharma S.A. | Methods and compositions for diseases associated with amyloidosis |
IT1319277B1 (it) | 2000-10-24 | 2003-09-26 | Chiesi Farma Spa | Proteine di fusione utili per il trattamento di immunizzazione dellamalattia di alzheimer. |
IL139308A0 (en) | 2000-10-26 | 2001-11-25 | Marikovsky Moshe | Peptides from amyloid precursor protein which inhibit tumor growth and metastasis |
DE60128138T2 (de) * | 2000-11-02 | 2008-01-03 | Cornell Research Foundation, Inc. | In vivo multiphoton diagnostische detektion und bilddarstellung einer neurodegenerativen erkrankung |
EP1346041B1 (de) * | 2000-11-27 | 2007-02-28 | Praecis Pharmaceuticals Incorporated | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
TWI255272B (en) * | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
AU2002246734A1 (en) * | 2000-12-27 | 2002-08-12 | University Of Texas Health Science Center Houston | Prion isomers, methods of making, methods of using, and compositions and products comprising prion isomers |
WO2002059621A2 (en) * | 2001-01-24 | 2002-08-01 | Bayer Corporation | Regulation of transthyretin to treat obesity |
EP1251138B1 (de) * | 2001-04-19 | 2006-07-26 | Hermann Dr. Schätzl | Prion Proteindimere für Impfungen |
ATE409047T1 (de) | 2001-04-30 | 2008-10-15 | Lilly Co Eli | Humanisierte antikörper |
EP1385545B1 (de) * | 2001-04-30 | 2009-01-07 | Eli Lilly And Company | HUMANISIERTE ANTIKÖRPER DIE DAS BETA-AMYLOID PEPTID ERKENNEN& x9; |
US6524624B1 (en) * | 2001-05-16 | 2003-02-25 | Alcide Corporation | Two-part disinfecting systems and compositions and methods related thereto |
US6906169B2 (en) * | 2001-05-25 | 2005-06-14 | United Biomedical, Inc. | Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide |
GB0113179D0 (en) | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
US6888849B2 (en) * | 2001-06-15 | 2005-05-03 | Lucent Technologies Inc. | Method for evaluating capacity utilization of a terminus in a communication system |
AU2002345843A1 (en) | 2001-06-22 | 2003-01-08 | Panacea Pharmaceuticals, Inc. | Compositions and methods for preventing protein aggregation in neurodegenerative diseases |
DE60235013D1 (de) | 2001-07-25 | 2010-02-25 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
US20030135035A1 (en) | 2001-08-09 | 2003-07-17 | Mark Shannon | Human ZZAP1 protein |
US20060073149A1 (en) | 2001-08-17 | 2006-04-06 | Bales Kelly R | Rapid improvement of cognition in condition related to abeta |
CA2451998A1 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | Anti-a.beta. antibodies |
JP2005500389A (ja) | 2001-08-17 | 2005-01-06 | イーライ・リリー・アンド・カンパニー | Aβに関連する病態および疾患を治療するための、可溶性Aβに高い親和性を有する抗体の使用 |
US20030082191A1 (en) | 2001-08-29 | 2003-05-01 | Poduslo Joseph F. | Treatment for central nervous system disorders |
ATE478556T1 (de) * | 2001-09-10 | 2010-09-15 | Anticancer Inc | Verbesserte beobachtungsgenauigkeit bei der absiedelung von tumoren |
US6736142B2 (en) * | 2001-09-13 | 2004-05-18 | Gines Sanchez Gomez | Protective tube and harness |
US6907297B2 (en) | 2001-09-28 | 2005-06-14 | Ethicon, Inc. | Expandable intracardiac return electrode and method of use |
US6597198B2 (en) * | 2001-10-05 | 2003-07-22 | Intel Corporation | Current mode bidirectional port with data channel used for synchronization |
GB0124446D0 (en) * | 2001-10-11 | 2001-12-05 | Short Brothers Ltd | Aircraft propulsive power unit |
US7781413B2 (en) | 2001-10-31 | 2010-08-24 | Board Of Regents, The University Of Texas System | SEMA3B inhibits tumor growth and induces apoptosis in cancer cells |
NZ532896A (en) | 2001-11-08 | 2007-08-31 | Pdl Biopharma Inc | Stable liquid pharmaceutical formulation of IGG antibodies including daclizumab and fontolizumab |
AU2002357007A1 (en) * | 2001-11-21 | 2003-06-10 | New York University | SYNTHETIC IMMUNOGENIC BUT NON-DEPOSIT-FORMING POLYPEPTIDES AND PEPTIDES HOMOLOGOUS TO AMYLOID Beta, PRION PROTEIN, AMYLIN, Alpha-SYNUCLEIN, OR POLYGLUTAMINE REPEATS FOR INDUCTION OF AN IMMUNE RESPONSE THERETO |
US20050227941A1 (en) | 2001-12-17 | 2005-10-13 | Karen Duff | Sequestration of ass in the periphery in the absence of immunomodulating agent as a therapeutic approach for the treatment or prevention of beta-amyloid related diseases |
AR038568A1 (es) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
US6688651B2 (en) * | 2002-02-21 | 2004-02-10 | Dmt Co., Ltd. | Device for locking cap nut for coupling |
JP2005526044A (ja) | 2002-02-21 | 2005-09-02 | デューク ユニバーシティ | 抗cd22抗体を使用した治療方法 |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
CA2390700C (en) * | 2002-06-11 | 2004-09-07 | Henry Tsang | Illuminated soap bar with sound |
GB0213437D0 (en) | 2002-06-12 | 2002-07-24 | Univ Cranfield | Temporary tattoos: A novel vehicle for skin testing |
US6892535B2 (en) * | 2002-06-14 | 2005-05-17 | Volvo Construction Equipment Holding Sweden Ab | Hydraulic circuit for boom cylinder combination having float function |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
CN101711865A (zh) | 2002-07-19 | 2010-05-26 | 希托斯生物技术股份公司 | 含有淀粉样β1-6抗原阵列的疫苗组合物 |
EP1911765A3 (de) | 2002-07-24 | 2008-04-23 | Innogenetics N.V. | Vorbeugung, Behandlung und Diagnose von Erkrankungen im Zusammenhang mit Beta-Amyloid-Bildung und/oder -Aggregation |
CA2501091A1 (en) | 2002-10-01 | 2004-04-15 | Northwestern University | Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof |
US20040080762A1 (en) * | 2002-10-25 | 2004-04-29 | Xerox Corporation | Half-tone based enhancement of black |
US20060019850A1 (en) * | 2002-10-31 | 2006-01-26 | Korzenski Michael B | Removal of particle contamination on a patterned silicon/silicon dioxide using dense fluid/chemical formulations |
FR2846667B1 (fr) | 2002-11-06 | 2004-12-31 | Pasteur Institut | Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives |
AU2003293543A1 (en) | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
US6787129B1 (en) | 2003-01-13 | 2004-09-07 | Zenitech Llc | Castor polyester as gloss agents in anionic systems |
ZA200505782B (en) * | 2003-02-01 | 2006-09-27 | Neuralab Ltd | Active immunization to generate antibodies to soluble A-beta |
WO2004071408A2 (en) | 2003-02-10 | 2004-08-26 | Applied Molecular Evolution, Inc. | Aβ BINDING MOLECULES |
WO2004091658A1 (en) | 2003-04-04 | 2004-10-28 | Genentech, Inc. | High concentration antibody and protein formulations |
EP1480041A1 (de) | 2003-05-22 | 2004-11-24 | Innogenetics N.V. | Verfahren zur Voraussage, zur Diagnose und zur vergleichenden Diagnose von Alzheimer |
PE20050627A1 (es) * | 2003-05-30 | 2005-08-10 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
US20060182321A1 (en) | 2003-07-07 | 2006-08-17 | Agency For Science, Technology And Research | Method and apparatus for extracting third ventricle information |
WO2005014041A2 (en) | 2003-07-24 | 2005-02-17 | Novartis Ag | Use of an amyloid beta dna vaccine for the treatment and/or prevention of amyloid diseases |
US20060233788A1 (en) | 2003-09-05 | 2006-10-19 | Heiman Mark L | Anti-ghrelin antibodies |
CA2445743A1 (en) | 2003-10-08 | 2005-04-08 | The University Of British Columbia | Methods for modulating neuronal responses |
WO2005035753A1 (ja) | 2003-10-10 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 機能蛋白質を代替する二重特異性抗体 |
AR047062A1 (es) | 2003-12-17 | 2006-01-04 | Wyeth Corp | Conjugados portadores de peptidos inmunogenicos a beta y metodos para producirlos |
AU2004299501B2 (en) | 2003-12-17 | 2010-12-23 | Wyeth Llc | Immunogenic peptide carrier conjugates and methods of producing same |
US20050214222A1 (en) | 2004-02-13 | 2005-09-29 | Mckinnon Stuart J | In vivo imaging of amyloid plaques in glaucoma using intravenous injectable dyes |
TWI361069B (en) | 2004-03-15 | 2012-04-01 | Janssen Pharmaceutica Nv | Novel compounds as opioid receptor modulators |
CN101137397A (zh) | 2004-07-02 | 2008-03-05 | 匹兹堡大学高等教育联邦体系 | 淀粉样蛋白成像作为抗淀粉样蛋白疗法的功效的替代标记物 |
MX2007000998A (es) | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
US7328838B2 (en) * | 2004-09-09 | 2008-02-12 | Igt | Counterfeit cashless instrument detection methods and systems |
PA8645301A1 (es) | 2004-09-10 | 2006-07-03 | Wyeth Corp | Anticuerpo anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina |
US7807804B2 (en) | 2004-10-05 | 2010-10-05 | Wyeth Llc | Methods and compositions for improving recombinant protein production |
US20060160161A1 (en) | 2004-10-26 | 2006-07-20 | Elan Pharmaceuticals, Inc. | Methods for assessing antibodies to neurodegenerative disease-associated antigens |
US20060026911A1 (en) * | 2004-11-18 | 2006-02-09 | Sutton Adam F | Footer track with moisture vent |
US20060240486A1 (en) | 2004-12-15 | 2006-10-26 | Johnson-Wood Kelly L | Immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies |
PE20061152A1 (es) | 2004-12-15 | 2006-10-13 | Neuralab Ltd | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
WO2006066118A2 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Contextual fear test for predicting efficacy of alzheimer immunotherapeutic treatment |
JP2008524247A (ja) | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミテッド | 認知の改善における使用のためのアミロイドβ抗体 |
AR052051A1 (es) | 2004-12-15 | 2007-02-28 | Neuralab Ltd | Anticuerpos ab humanizados usados en mejorar la cognicion |
BRPI0606867A2 (pt) | 2005-01-28 | 2009-07-21 | Wyeth Corp | formulação lìquida; forma de dosagem unitária farmacêutica; kit; recipiente; método para aumentar a estabilidade de um polipeptìdeo de ligação a antìgeno numa formulação; método para preparar uma forma de dosagem unitária farmacêutica; formulação estável; formulação; e produto terapêutico |
GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
RU2406529C2 (ru) | 2005-05-05 | 2010-12-20 | Мерк Шарп Энд Домэ Корп. | Композиции пептидного конъюгата и способы для профилактики и лечения болезни альцгеймера |
EA201100177A1 (ru) | 2005-06-17 | 2011-06-30 | Элан Фарма Интернэшнл Лимитед | СПОСОБЫ ОЧИСТКИ АНТИТЕЛ К β-АМИЛОИДУ |
CN101238124A (zh) | 2005-07-18 | 2008-08-06 | 默克公司 | 用于治疗阿尔茨海默氏病的螺哌啶β-分泌酶抑制剂 |
KR20080095836A (ko) * | 2005-11-10 | 2008-10-29 | 로스캄프 리서치 엘엘씨 | A―베타 펩티드 단편에 의한 혈관형성의 조정 |
BRPI0709246A2 (pt) | 2006-03-30 | 2011-07-12 | Glaxo Group Ltd | anticorpo terapêutico, composição farmacêutica, método de tratamento de um paciente humano acometido com uma doença relacionada com peptìdeo beta-amilóide, uso de um anticorpo terapêutico, e, anticorpo ou fragmento do mesmo |
WO2009017467A1 (en) | 2007-07-27 | 2009-02-05 | Elan Pharma International Limited | Treatment of amyloidogenic diseases |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
WO2010044803A1 (en) | 2008-10-17 | 2010-04-22 | Elan Pharma International Limited | Treatment of amyloidogenic diseases |
WO2008011348A2 (en) | 2006-07-14 | 2008-01-24 | Ac Immune S.A. | Humanized antibody against amyloid beta |
WO2008114801A1 (en) | 2007-03-12 | 2008-09-25 | National Institute Of Radiological Sciences | Pet visualization of amyloid-associated neuroinflammation in the brain |
EP2146746A4 (de) | 2007-04-18 | 2011-03-23 | Janssen Alzheimer Immunotherap | Vorbeugung und behandlung von zerebraler amyloid-angiopathy |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
US9272030B2 (en) | 2007-10-17 | 2016-03-01 | Janssen Sciences Ireland Uc | Use of tau to monitor immunotherapy |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
SG186689A1 (en) | 2007-12-28 | 2013-01-30 | Univ Tennessee Res Foundation | Treatment and prophylaxis of amyloidosis |
WO2010033861A1 (en) | 2008-09-18 | 2010-03-25 | Cedars-Sinai Medical Center | Optical method for the detection of alzheimer's disease |
EP2538982A4 (de) | 2010-02-25 | 2016-02-17 | Janssen Alzheimer Immunotherap | Pet-überwachung einer auf a-beta gezielten immuntherapie |
-
1998
- 1998-11-26 TW TW087119660A patent/TWI239847B/zh not_active IP Right Cessation
- 1998-11-30 EE EEP200000379A patent/EE05377B1/xx unknown
- 1998-11-30 KR KR1020007005913A patent/KR100936419B1/ko active IP Right Grant
- 1998-11-30 DE DE06075479T patent/DE06075479T1/de active Pending
- 1998-11-30 EA EA200601132A patent/EA009283B1/ru not_active IP Right Cessation
- 1998-11-30 DK DK06075479T patent/DK1679080T3/da active
- 1998-11-30 DE DE1033996T patent/DE1033996T1/de active Pending
- 1998-11-30 BR BR9815357-9A patent/BR9815357A/pt not_active Application Discontinuation
- 1998-11-30 SG SG200205898A patent/SG111083A1/en unknown
- 1998-11-30 ES ES06075704T patent/ES2262460T1/es active Pending
- 1998-11-30 GE GE5511A patent/GEP20053715B/en unknown
- 1998-11-30 KR KR1020127028217A patent/KR20120135915A/ko not_active Application Discontinuation
- 1998-11-30 PL PL384504A patent/PL202706B1/pl unknown
- 1998-11-30 CN CNB988117312A patent/CN100374151C/zh not_active Expired - Lifetime
- 1998-11-30 AT AT08011409T patent/ATE493149T1/de active
- 1998-11-30 DE DE69842082T patent/DE69842082D1/de not_active Expired - Lifetime
- 1998-11-30 DK DK10182575.0T patent/DK2305282T3/da active
- 1998-11-30 ES ES06075479T patent/ES2263408T3/es not_active Expired - Lifetime
- 1998-11-30 ID IDW20001293A patent/ID25504A/id unknown
- 1998-11-30 IL IL13625298A patent/IL136252A0/xx unknown
- 1998-11-30 EP EP08011409A patent/EP1994937B1/de not_active Revoked
- 1998-11-30 EA EA200401473A patent/EA007218B1/ru not_active IP Right Cessation
- 1998-11-30 AT AT06075704T patent/ATE435659T1/de not_active IP Right Cessation
- 1998-11-30 SI SI9830921T patent/SI1679080T1/sl unknown
- 1998-11-30 SI SI9830942T patent/SI2305282T1/sl unknown
- 1998-11-30 CZ CZ20001706A patent/CZ303137B6/cs not_active IP Right Cessation
- 1998-11-30 PT PT08011409T patent/PT1994937E/pt unknown
- 1998-11-30 EP EP06075704A patent/EP1690547B1/de not_active Revoked
- 1998-11-30 AT AT98961833T patent/ATE399016T1/de active
- 1998-11-30 EP EP10182575.0A patent/EP2305282B1/de not_active Revoked
- 1998-11-30 DK DK08011409.3T patent/DK1994937T3/da active
- 1998-11-30 ES ES98961833T patent/ES2310017T3/es not_active Expired - Lifetime
- 1998-11-30 AT AT06075479T patent/ATE433760T1/de active
- 1998-11-30 CA CA2312920A patent/CA2312920C/en not_active Expired - Lifetime
- 1998-11-30 ES ES10182575T patent/ES2428740T3/es not_active Expired - Lifetime
- 1998-11-30 WO PCT/US1998/025386 patent/WO1999027944A1/en active Application Filing
- 1998-11-30 PL PL384503A patent/PL202698B1/pl unknown
- 1998-11-30 KR KR1020097011537A patent/KR101248711B1/ko active IP Right Grant
- 1998-11-30 NZ NZ504569A patent/NZ504569A/en not_active IP Right Cessation
- 1998-11-30 AR ARP980106063A patent/AR020050A1/es not_active Application Discontinuation
- 1998-11-30 DE DE69840969T patent/DE69840969D1/de not_active Expired - Lifetime
- 1998-11-30 SI SI9830928T patent/SI1994937T1/sl unknown
- 1998-11-30 HU HU0100627A patent/HU228061B1/hu unknown
- 1998-11-30 PT PT06075479T patent/PT1679080E/pt unknown
- 1998-11-30 SI SI9830911T patent/SI1033996T1/sl unknown
- 1998-11-30 EA EA200000608A patent/EA200000608A1/ru unknown
- 1998-11-30 GE GE3977A patent/GEP20043319B/en unknown
- 1998-11-30 PE PE1998001161A patent/PE20001383A1/es not_active IP Right Cessation
- 1998-11-30 EP EP06075479A patent/EP1679080B1/de not_active Revoked
- 1998-11-30 EP EP98961833A patent/EP1033996B1/de not_active Revoked
- 1998-11-30 DE DE06075704T patent/DE06075704T1/de active Pending
- 1998-11-30 DE DE69839647T patent/DE69839647D1/de not_active Expired - Lifetime
- 1998-11-30 HU HU1200431A patent/HU228493B1/hu unknown
- 1998-11-30 JP JP2000522929A patent/JP4677094B2/ja not_active Expired - Lifetime
- 1998-11-30 AU AU17061/99A patent/AU1706199A/en not_active Abandoned
- 1998-11-30 PT PT98961833T patent/PT1033996E/pt unknown
- 1998-11-30 DE DE69840922T patent/DE69840922D1/de not_active Expired - Lifetime
- 1998-11-30 DK DK98961833T patent/DK1033996T3/da active
- 1998-11-30 TR TR2000/01608T patent/TR200001608T2/xx unknown
- 1998-11-30 PT PT101825750T patent/PT2305282E/pt unknown
- 1998-12-01 MY MYPI98005427A patent/MY134906A/en unknown
- 1998-12-01 CO CO98071271A patent/CO4980846A1/es unknown
-
1999
- 1999-04-06 SA SA99191269A patent/SA99191269B1/ar unknown
-
2000
- 2000-05-17 IS IS5500A patent/IS5500A/is unknown
- 2000-05-21 IL IL136252A patent/IL136252A/en not_active IP Right Cessation
- 2000-05-31 NO NO20002784A patent/NO328865B1/no not_active IP Right Cessation
- 2000-06-27 BG BG104562A patent/BG104562A/xx unknown
- 2000-06-30 HR HR20000443A patent/HRP20000443B1/xx not_active IP Right Cessation
-
2003
- 2003-11-07 US US10/703,713 patent/US20040171815A1/en not_active Abandoned
- 2003-11-07 US US10/704,070 patent/US20040171816A1/en not_active Abandoned
-
2004
- 2004-02-27 US US10/789,273 patent/US20050249725A1/en not_active Abandoned
- 2004-03-31 US US10/816,380 patent/US7014855B2/en not_active Expired - Lifetime
- 2004-03-31 US US10/815,353 patent/US6808712B2/en not_active Expired - Lifetime
- 2004-03-31 US US10/815,404 patent/US6982084B2/en not_active Expired - Lifetime
- 2004-08-20 US US10/923,471 patent/US8535673B2/en not_active Expired - Fee Related
- 2004-08-20 US US10/923,469 patent/US8034339B2/en not_active Expired - Fee Related
- 2004-08-20 US US10/923,605 patent/US20050249727A1/en not_active Abandoned
- 2004-08-20 US US10/923,267 patent/US20050191292A1/en not_active Abandoned
- 2004-08-20 US US10/923,474 patent/US20050048049A1/en not_active Abandoned
- 2004-08-27 US US10/928,926 patent/US20050196399A1/en not_active Abandoned
- 2004-09-02 US US10/934,819 patent/US20050163788A1/en not_active Abandoned
- 2004-09-02 US US10/933,559 patent/US6972127B2/en not_active Expired - Lifetime
- 2004-09-02 US US10/934,609 patent/US6946135B2/en not_active Expired - Lifetime
-
2005
- 2005-02-14 US US11/058,757 patent/US20050142132A1/en not_active Abandoned
- 2005-04-15 US US11/108,102 patent/US20050191314A1/en not_active Abandoned
- 2005-10-07 US US11/245,916 patent/US20060029611A1/en not_active Abandoned
- 2005-10-07 US US11/245,524 patent/US20060034858A1/en not_active Abandoned
- 2005-11-30 JP JP2005346462A patent/JP4677333B2/ja not_active Expired - Lifetime
- 2005-11-30 JP JP2005346511A patent/JP4677334B2/ja not_active Expired - Lifetime
-
2007
- 2007-01-12 HK HK07100441.8A patent/HK1095265A1/xx not_active IP Right Cessation
- 2007-02-13 HK HK07101687.9A patent/HK1094535A1/xx not_active IP Right Cessation
- 2007-08-20 US US11/842,120 patent/US20080227719A1/en not_active Abandoned
- 2007-08-20 US US11/842,116 patent/US8642044B2/en not_active Expired - Lifetime
- 2007-08-20 US US11/842,085 patent/US20080096818A1/en not_active Abandoned
- 2007-08-20 US US11/842,113 patent/US8034348B2/en not_active Expired - Fee Related
-
2008
- 2008-06-03 IL IL191904A patent/IL191904A/en not_active IP Right Cessation
- 2008-08-05 IL IL193245A patent/IL193245A0/en unknown
- 2008-09-10 CY CY20081100977T patent/CY1108331T1/el unknown
-
2009
- 2009-08-21 NO NO20092874A patent/NO331425B1/no not_active IP Right Cessation
- 2009-09-16 CY CY20091100951T patent/CY1109368T1/el unknown
- 2009-10-26 HR HR20090568A patent/HRP20090568A2/hr not_active Application Discontinuation
-
2010
- 2010-01-15 NO NO20100061A patent/NO332813B1/no not_active IP Right Cessation
- 2010-04-22 IL IL205298A patent/IL205298A0/en unknown
- 2010-06-01 JP JP2010126015A patent/JP2010215651A/ja active Pending
-
2011
- 2011-03-28 CY CY20111100331T patent/CY1111370T1/el unknown
- 2011-10-10 US US13/270,015 patent/US20130058869A1/en not_active Abandoned
- 2011-10-11 US US13/271,081 patent/US20120276116A1/en not_active Abandoned
-
2013
- 2013-09-03 US US14/017,177 patent/US20140227274A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0526511B1 (de) * | 1990-04-27 | 1997-05-28 | MCMICHAEL, John | Verfahren und zusammensetzung zur behandlung von erkrankungen des zns hervorgerufen durch abnormales beta-amyloid-protein |
EP0683234A1 (de) * | 1993-01-25 | 1995-11-22 | Takeda Chemical Industries, Ltd. | ANTIKÖRPER GEGEN -g(b)-AMYLOID ODER DERIVATE DAVON UND SEINE VERWENDUNG |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG111083A1 (en) | Prevention and treatment of amyloidogenic disease | |
GB2368794B (en) | Prevention and treatment of amyloidogenic disease | |
HUP0201205A2 (en) | Prevention and treatment of amyloidogenic disease | |
EP1030663A4 (de) | Behandlung von fibromyalgie und verwandten erkrankungen | |
IL138692A0 (en) | Treatment and prevention of vascular disease | |
IL141211A0 (en) | Prevention and treatment of viral disease | |
EP1173189A4 (de) | Asialozytokine und behandlung von leber erkrankungen | |
EP0833641A4 (de) | Behandlung und vorbeugung von erkrankungen der prostata | |
ZA9810932B (en) | Prevention of and treatment of amyloidogenic disease. | |
AU2003203740A1 (en) | Prevention and treatment of amyloidogenic disease | |
GB9516572D0 (en) | Prevention and/or treatment of disease | |
GB0030865D0 (en) | Treatment and prevention of disease | |
GB0030866D0 (en) | Treatment and prevention of disease | |
GB0016197D0 (en) | Treatment and prevention of disease | |
GB9510961D0 (en) | Hemorrhoid treatment and prevention | |
GB9410969D0 (en) | Hemorrhoid treatment and prevention | |
GB9710054D0 (en) | Treatment of diseases | |
IL118475A0 (en) | Treatment of skin spots and prevention of their formation | |
GB9726745D0 (en) | Treatment of medical conditions | |
IL121656A0 (en) | Diagnosis prevention and treatment of diabetes | |
GB9712879D0 (en) | Hyperbaric lesion treatment |